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CK2 negatively regulates 5-HT4 receptor signaling in the prefrontal cortex and mediates depression-like 
behaviors 
by  
Julia Castello Saval 
 
Abstract 
Advisor: Dr. Eitan Friedman  
 
The serotonergic system has been the major candidate in the pathophysiology of mood related disorders 
such as anxiety and major depressive disorder (MDD). Unfortunately, current antidepressant drugs are 
ineffective in 50% of the population and require chronic administration for a period of 3-6 weeks before the 
onset of therapeutic response. 5-HT4 receptor (5-HT4R) agonists have emerged as potential candidates 
for fast antidepressant action, since an antidepressant response can be achieved after 3 days of 
pharmacological administration in rodents.  
This dissertation aims to investigate the role of casein kinase 2 (CK2) as a regulator of 5-HT4R expression 
and activity using in vitro techniques and in vivo mouse models. We present evidence, in two different CK2α 
conditional knockout (KO) mouse lines, that CK2 regulation of 5-HT4R is region specific in the brain. When 
CK2α is ablated, 5-HT4R mRNA expression is upregulated in the medial PFC (mPFC) but not in other 
regions where CK2α is also absent like the striatum or the hippocampus. In vitro, 5-HT4R signaling and 
expression at the plasma membrane is enhanced after shRNA knockdown or pharmacological inhibition of 
CK2. In vivo, 5-HT4R is also upregulated as evidenced by increased pERK expression in the mPFC that is 
sensitive to 5-HT4R antagonist treatment, GR113808, of the CK2α KO mice. Behaviorally, the CK2α KO 
mice present an antidepressed and anxiolytic-like phenotype in a battery of tests of behavioral despair and 
they are more sensitive to antidepressant treatment when compared to wild-type (WT) littermates. 
Interestingly, AAV9-mediated knockdown of CK2α in the mPFC of adult mice is sufficient to phenocopy the 
behavior of the CK2α KO animals. Although AAV9-HTR4-shRNA-mediated reduction of HTR4 expression 
in the mPFC of CK2α lead only to partial rescue of the phenotype, it was sufficient to overexpress 5-HT4R 
 
 v 
in the mPFC to generate mice with an antidepressed- and an anxiolytic- like behavior. In addition, AAV9-
mediated knockdown of CK2α but not 5-HT4R overexpression lead to increased neurogenesis in the ventral 
hippocampus. This was paralleled by an impairment in spatial learning and indicated that while the CK2-
mediated regulation of 5-HT4R is specific to the mPFC and responsible for the antidepressed and anxiolytic-
like phenotype, CK2 might also act through a 5-HT4R-independent mechanism responsible to act on 
aspects of cognition and neurogenesis. 
In summary, my work identifies CK2 as a region-specific negative regulator of 5-HT4R levels and activity 
and provides evidence that manipulation of CK2 through the upregulation of the 5-HT4R is responsible for 
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Chapter 1  
Introduction 
Adapted from the 2018 publication: Heike Rebholz, Eitan Friedman and Julia Castello. “Alterations of 
expression of the serotonin 5-HT4 receptor in brain disorders” Internationa Journal of Molecular Sciences 
(2018) 19(11), 3581 
 
1.1 Major depressive disorder 
Major depressive disorder (MDD) affects 17% of the US population. According to the World Health 
Organization, 450 million people worldwide suffer from the disease and it is predicted to be the leading 
cause of disability by 20301. Depression is rare in children and sex differences emerge during adolescence. 
In adolescents and adults, females are twice more at risk than males2,3 
The most common MDD symptoms, according to the Diagnostic and Statistical manual of Mental Disorders 
5 (DSM V) are sadness, feelings of emptiness or hopelessness throughout most of the day; anhedonia 
(which refers to the inability of experiencing pleasure), irritability, weight loss or weight gain, increased or 
decreased appetite, abnormal sleep (insomnia or hypersomnia), agitation or fatigue, loss of energy, low 
self-esteem, excessive guilt, inability to focus as well as impaired decision making and ultimately, suicidal 
thoughts. An individual presenting 5 of these symptoms nearly everyday is diagnosed with MDD meaning 
that there are a total of 227 possibilities to meet the symptom criteria for MDD4 and due to the large 
heterogeneity of the disease, its study becomes very challenging. 
MDD is often preceded by long-term anxiety and it comes to no surprise that 60% of the patients suffering 
from MDD present comorbidity with anxiety disorders5 sharing both emotional negative states and over 
activation of the same neural circuits like amygdala and anterior cingulate cortex6. In normal conditions, 
anxiety states are helpful in identifying threat7: transient rise in cortisol levels triggers the fight-or-flight 
response, boosts energy levels and improves confidence but dysregulation of cortisol levels by over activity 




threat, that can ultimately cause depression8,9.  The consequences of sustained stress are hippocampal 
atrophy, which include retraction of dendritic neurons, inhibition of neurogenesis and loss of preformed 
adult hippocampal neurons altogether resulting in a loss of hippocampal volume. These neurological 
degradations have become key neurological markers in MDD10-12.  
1.2. Treatment of Major Depressive Disorder 
Cognitive behavioral therapy or psychotherapy can be effective in treating mild depression but 
antidepressant drugs are needed for MDD. In cases where pharmacological administration is not effective 
or the patient is too debilitated, electroconvulsive treatment can provide an acute effective response13,14 but 
the side effects include partial memory impairment and retrograde amnesia15. As an alternative, targeted 
stimulation like deep brain stimulation and transcranial magnetic stimulation can ameliorate the symptoms 
of depression16. 
Nowadays, the most prescribed antidepressant drugs to treat MDD act on the monoaminergic system 
comprised of the three neurotransmitters: serotonin (5-HT), dopamine (DA) and norepinephrine (NE). The 
first generation of antidepressant drugs are monoamine oxidase inhibitors (MAOI) and tricyclic 
antidepressant (TCA) drugs. MAOIs were discovered by serendipity in 195117. MAOI impair the ability of 
the MAO enzyme to breakdown 5-HT, DA and NE. TCAs include imipramime, amitriptyline, desipramine 
and cloropramine and their mechanism of action is by blockade of serotonin and/or norepinephrine 
transporters18. Both MAOI and TCA increase the availability of monoamines at the presynaptic terminal. 
First generation antidepressants are rarely prescribed due to its strong side effects including memory and 
cognitive deficits, blurry vision, dizziness, mouth drying, urinary retention and hypotension in TCA19 and 
withdrawal symptoms, dietary restrictions and toxicity with risk of overdose in MAOI20. 
The second generation of antidepressant drugs are selective serotonin reuptake inhibitors (SSRIs) and are 
the most commonly used worldwide. They are prescribed to treat depression and anxiety disorders and, in 
high doses, obsessive-compulsive disorder21. They include citalopram, escitalopram, fluoxetine, 
vilazodone, sertraline and paroxetine. They work by blockade of the serotonin transporter (SERT) inhibiting 
the reuptake of serotonin into the presynaptic terminal thus, enhancing serotonin levels at the synapse and 




receptors. Despite the amelioration of the side effects, SSRIs fail to be more effective than the first 
generation antidepressant drugs and are only successful in one third of the population23. Furthermore, their 
delayed onset of action of three to six weeks exposes a severe clinical problem24 since patients might 
experience frustration due to the lack of improvement in early phases of treatment leading to fatal 
consequences like increased suicidal thoughts. In addition, relapse might occur once treatment is ceased25. 
Therefore, there is an urgent need for alternative treatments with rapid onset of action. 
1.3. Etiology of Major depressive disorder 
MDD is caused by a combination of environmental, genetic heterogeneity and neurological factors. The 
cathecholamine hypothesis26 and the later serotonin hypothesis formulated by Coppen27 phrased that 
depression is triggered by a lack of serotonin in the brain and can be reversed by an increase of serotonin 
levels. Although this statement is nowadays simplistic, the serotonergic system has remained the focus of 
attention in the understanding of MDD. Decreased 5-HT transmission correlates with MDD28, and this 
function is restored after antidepressant treatment29. In addition, depressed patients present lower levels 
of plasma tryptophan30, a 5-HT precursor, and lower levels of 5-H1AA, a 5-HT metabolite, in the 
cerebrospinal fluid29. Also, they show a blunted inhibitory hormonal response when they confront a 
serotonergic challenge and a decreased serotonergic response in the brain31. 
Despite the correlation between MDD and the serotonergic system dysfunction, it is imperative to clearly 
understand the etiology of the disease in order to identify new targets that can overcome the lack of 
efficiency of SSRIs as well as their delayed onset of action. 
1.4 The serotonergic system 
The serotonergic system is comprised of 250 000 neurons out of 1011 total neurons in the human brain 
creating the second largest population of neurons after the glutamate network32. The largest nucleus of 
serotonergic neurons originates from the dorsal raphe nucleus (DRN), located in the brainstem. 
Serotonergic neurons are larger than any other cells and have cell bodies with axons projecting throughout 
the whole brain and spinal cord creating a complex network regulated by several different mechanisms33. 




inputs from the PFC, noradrenergic inputs from the pontine nuclei, inhibitory GABA-ergic inputs from local 
interneurons and dopaminergic inputs from the midbrain dopaminergic nuclei as well as self-regulation via 
inhibition of 5-HT1A autoreceptors34.  
1.5. Serotonin receptors and antidepressant action 
Several 5-HT receptors have been discussed as mediators of antidepressant action. 5-HT1A autoreceptors 
play a critical role for being a key component in the negative feedback loop of the DRN, where increased 
5-HT will stimulate presynaptic 5-HT1A autoreceptors counteracting the effect of SSRIs35 (Image 1.1). 
Interestingly, the time period required for antidepressant efficacy (3 to 6 weeks) coincides with the 
timeframe necessary for 5-HT1A autoreceptor desensitization35. Supporting evidence show that patients 
with increased density of 5-HT1A autoreceptors are more susceptible to suffer mood disorders and are less 
responsive to antidepressants36,37. In postmortem and neuroimaging studies, increased density of 5-HT1A 
autoreceptors in MDD patients is detected without change in postsynaptic 5-HT1A receptors38. In addition, 
5-HT1A knockout (KO) mice show an antidepressed-like phenotype39. Chronic antidepressant treatment 
increases hippocampal neurogenesis mediated through activation of 5-HT1A receptors in the dentate 
gyrus40. Nevertheless, administration of 5-HT1A receptor agonist has not been more efficient than SSRIs. 
This might be caused by the preferential activation of the presynaptic receptors thus, decreasing 5-HT firing 
and release in addition of a low specificity towards targeting postsynaptic receptors41. The contribution of 
other 5-HT receptors to MDD and to the mechanism of action of antidepressants cannot be excluded and 





Table 1.1. Summary of the most relevant 5-HT receptors and their in vivo outcomes in depression 





1.6. The 5-HT4 receptor 
 
The 5-HT4R has received significant attention in the context of MDD. 5-HT4R are G protein-coupled 
receptors (GPCRs) coupled to Gαs. They are mainly located in the putamen, caudate nucleus, nucleus 
accumbens, hippocampus, globus pallidus and substantia nigra and less predominantly in the neocortex, 
raphe and pontine nuclei as well as some areas of the thalamus43.  
Firing of the DRN can be increased through administration of 5-HT4R agonists and significantly decreased 
with 5-HT4R antagonists. Also, the 5-HT4R KO mice 44 present lower firing of serotonergic neurons in the 
DRN. In particular, 5-HT4R overexpression in the medial pre frontal cortex (mPFC) has been shown to 
enhance  firing of DRN neurons, establishing 5-HT4R as a major player in the PFC-DRN positive feedback 
loop (Image 1.1)45. Furthermore, chronic administration of 5-HT4R agonist enhanced 5-HT4R activity which 
peaks after 3 days of treatment without undergoing desensitizatio thus keeping the positive feedback loop 
intact over a prolonged period of time45 leading to increased synaptic 5-HT levels and desensitization of 5-
HT1A autoreceptors45. In addition, rats treated with partial agonist RS67333 showed increased post-
synaptic 5-HT1A receptor function in hippocampal CA3 pyramidal cells, phosphorylation of cAMP response 












Behaviorally, partial agonists RS67333 or SL650155 have been described as rapid acting antidepressant 
drugs in preclinical rodent models of depression47-51. The therapeutic response to subchronic and chronic 
administration of 5-HT4R agonists or fluoxetine in rodents to most depression and anxiety assessment tests 
is independent of neurogenesis and only the novelty suppressed feeding test require hippocampal 
neurogenesis in order to achieve the beneficial effects of antidepressants 51. The behavioral effects of 
fluoxetine are abolished when co-administered with the 5-HT4R antagonist GR125487 indicating that 5-
HT4R action is required to mediate the behavioral effects of fluoxetine46,51.  5-HT4R is upregulated in the 
cortex after fluoxetine treatment and this upregulation is required for the behavioral effects52. Taken all 
together, targeting 5-HT4R could become a new alternative treatment with fast onset of action. In addition, 
studies in humans show that patients with familial risk of depression and suicide exhibit reduced 5-HT4R 
binding53, and 5-HT4R gene (HTR4)  polymorphisms in the spliced variant region are associated with 
unipolar depression54.  
  
Image 3.1 Representation of the effects of SSRIs administration in the brain. Acute inhibition of SERT 
causes endogenous 5-HT release. 5-HT1A and 5-HT1B autoreceptors are activated in the DRN and modulate 
the firing rate of 5-HT neurons via the negative and positive feedback loops (blue and purple loops, 
respectively). Autoinhibition/ Desensitization of 5-HT1B autoreceptors in the axon terminals also takes place. 
5-HT1A and 5-HT4R in the PFC layer 5 pyramidal neurons modulate 5-HT firing by inhibiting and activating 
in a long-feedback loop, respectively (blue and orange arrows).  






1.7. Regulation of 5-HT4R expression 
Surprisingly, little is known about the transcriptional regulation of the HTR4 across tissues. The HTR4 
mRNA is transcribed from a very complex gene encompassing 38 exons spanning over 700 kb and multiple 
C-terminal isoforms are expressed in specific tissues in the CNS 55. To date, it is not known how 5-HT4R 
expression is regulated in the brain, and so far we have only rudimentary knowledge about the promoter, 
derived from human atrial tissue and placenta56,57. In the heart, the major transcription start site of the HTR4 
gene is located at −3185 bp upstream of the first start codon56. In placenta, the 5’-UTR is even longer, 
spanning over 5100 bp upstream from the translation start site57. The different 5’-UTRs upstream of the 
translation initiation codon are interesting since they may hold an additional key to understand region and 
cell-type specific regulation of protein expression.  The promoter lacks TATA and CAAT canonical motifs, 
but contains several transcription factor binding sites56. Interestingly, a short region of  200 bp was shown 
to drive transcription in human cells but not in monkey cells, indicating that regulation is species-specific56. 
These different transcriptional initiation sites might not alter the protein-coding region yet might alter the 
extent and pattern of expression of 5-HT4R. It is hypothesized that such long 5’-UTR reduces RNA 
translation and leads to low levels of expressed transcripts by causing premature initiation at a wrong ATG 
and preventing the ribosome from reaching the correct start codon58. In addition to the different lengths of 
5’-UTR there also exist isoforms in the 3’-UTR regions that are targets for post-transcriptional modification 
by non-coding RNAs such as miRNAs. For example, miR-16 and miR-103 downregulate 5-HT4R transcript 
levels in vitro and it was found that patients with irritable bowel syndrome present in the gastrointestinal 
track predominantly an isoform of 5-HT4R that lacks the binding sites for miR-16 and miR-10359. Let-7a is 
another miRNA that can regulate 5-HT4R60. 
There are at least 8 human 5-HT4R splice variants named a-d,g,h,I,n55,61-64. Isoforms a,b,c,g and n are 
highly expressed in the CNS. Mice have five isoforms65 known and rats have four64,66. To date, no specific 
isoform has been linked to a brain disorder.  
1.8. Post-translational regulation of 5-HT4R 
Different post-translational regulation mechanisms of 5-HT4R have been described in several in vitro 




are able to phosphorylate GPCRs in their intracellular domains to initiate endocytosis67. For example, GRK2 
phosphorylates and desensitizes 5-HT4R resulting in lower cAMP/PKA pathway activation68 and GRK5 
phosphorylates 5-HT4R activating ERK phosphorylation69.  
Palmitoylation (where a lipidic cysteine group undergoes esterification with a palmitoyl group generating a 
link to the lipid bilayer of the plasma membrane) allows for rapid regulation of protein function, affecting 
GPCR endocytosis, phosphorylation, desensitization and ultimately, cellular signaling. The mouse 5-HT4R 
a variant is pamitoylated at 3 highly conserved cysteine sites and at a C-terminal cysteine that is variant-
specific. When palmitoylation takes place near protein-protein interaction motifs it will affect the binding 
character of the receptor, constitutive activity or internalization.70,71 
One study shows that the 5-HT4R has two putative N-linked sites susceptible of glycosylation, one in the 
second extracellular loop and one at the N-terminus72.  
What is clearly missing in our understanding of all described post-translational modifications are data 
generated from physiologically expressed 5-HT4R such as in mouse brain, a comparison between brain 
regions and an analysis in response to drug treatment or of mental disease models. 
1.9. Regulators of the 5-HT4R 
5-HT4R expression changes have been identified in rodent models of depression and anxiety such as 
bulbectomy, glucocorticoid receptor heterozygous mice, social defeat stress or exposure to prenatal stress. 
As well as in other neurological diseases like obesity, Alzheimer’s disease, schizophrenia and Parkinson’s 
disease.  
Very few proteins have been identified as regulators of 5-HT4R expression. One of them is SERT or 5-HTT. 
Protein levels of 5-HT4R are altered in the 5-HTT KO and 5-HTT overexpressing mice. Precisely, 
autoradiography studies with [3H]SB207145 radioligand showed increased 5-HT4R binding in the 5-HTT 
OE mice in all brain regions but the amygdala. Inversely, in the 5-HTT KO mice, 5-HT4R binding is 
decreased in all regions studied. This is consistent with studies providing evidence that chronic treatment 
with SSRIs of healthy individuals decreased 5-HT4R binding through PET imaging73. Studies in rodents 




electrophysiological activity in the hippocampus74. In a similar fashion, mice overexpressing 5-HT4R in the 
mPFC exhibit stress-induced hypophagia and a corresponding 5-HT4R-dependent downregulation of SERT 
and 5-HT1A transcripts75. Oppositely, siRNA mediated knockdown of 5-HT4R in the mPFC induces 
hyperphagia75.  
These studies are important because they highlight that altered 5-HT concentration is most likely 
responsible for changes in 5-HT4R receptor binding as a compensatory mechanism as well as bi-
directionality of this process, since exogenous alterations in 5-HT4R levels induce changes in 5-HT 
availability negatively regulating the expression of SERT as well as other 5-HT receptors.  
S100 calcium effector protein p11 (S100A10), a depression marker protein, has been identified in a yeast-
based screening system as a binding partner of 5-HT4R, with greater affinity to 5-HT4R than to other 
serotonin receptors, like 5-HT1B and 5-HT1D 76. p11 co-localizes with 5-HT4R in brain regions that play an 
important role in MDD like cingulate cortex, hippocampus, amygdala and striatum as seen by in situ 
hybridization and immunohistochemistry using transgenic bac-GFP mice where GFP is expressed under 
the 5-HT4R promoter. p11 KO mice showed reduced 5-HT4R protein in radioligand binding assays, were 
behaviorally less sensitive to antidepressant treatment and did not respond to 5-HT4R agonist. As binding 
partner of 5-HT4R and adaptor protein for many other GPCRs, p11 recruits 5-HT4R to the site of its action, 
the plasma membrane76.  
Nav1.7 is a voltage-gated sodium channel required for nociceptive neuronal activation. While humans 
lacking Nav1.7 and genetic KO mice show absence of pain, a pharmacological antagonist of the receptor 
failed to decrease pain sensitivity, indicating that receptor-signaling-mediated activation of nociceptive 
neurons might not be the only mechanism involved in pain alleviation. For example, loss of Nav1.7 
coincided with upregulation of met-enkephalin, an endogenous opioid growth factor in sensory neurons, 
increasing opioid activity and anti-nociceptive signaling. In addition, Nav1.7 KO mice presented reduced 
levels of 5-HT4R in the dorsal root ganglia77. Both effects, changes in encephalin and 5-HT4R expression 





We found a novel regulator of the 5-HT4R.  In the mouse brain there is a region-specific negative 
transcriptional regulation exerted by CK2. CK2 is a constitutively active and ubiquitously expressed kinase 
that targets a myriad of substrates. We have identified CK2 as a negative regulator of the 5-HT4R both at 
the transcript level as well as the post-translational level.  Conditional KO of the catalytic subunit of CK2, 
CK2α, in the hippocampus, striatum and the cortex lead to an upregulation of 5-HT4R mRNA selectively in 
the PFC79. Furthermore, in luciferase assays, using a 4 KB upstream element fused to luciferase cDNA, 
expression was promoted when CK2 was inhibited or knocked down in HeLa cells but not in HEK293 or 
COS7 cells, underlining the importance of tissue-specifically expressed transcription factors. Knockdown 
or inhibition of CK2 in vitro, elevated 5-HT4R-dependent cAMP generation and increased receptor 
localization at the plasma membrane. And in vivo, CK2 KO mice presented an elevated 5-HT4R dependent 
pERK activation. Virally-mediated focal knockdown of CK2α or overexpression of 5-HT4R in the mPFC 
generated an anti-depressed and anxiolytic-like phenotype that was similar to the phenotypes observed 
with CK2α knockout in the forebrain driven by Emx1-Cre or Drd1a-Cre. In addition, such conditional CK2α 





Chapter 2  
Casein Kinase II structure and regulation in the brain 
Adapted from 2017 publication: Julia Castello, Andre Ragnauth, Eitan Friedman and Heike Rebholz. 
“CK2- an emerging target for Neurological and Psychiatric Disorders” Pharmaceuticals (2017) 10(1), 7 
 
2.1. Introduction  
2.1.1. Structure of CK2 
Casein Kinase II (CK2) is a heterotetramic enzyme consisting in two catalytic subunits (α and/or α’) and 
two regulatory subunits (β)80 (Image 2.1). It is constitutively active and ubiquitously expressed. CK2 is 
found in the nucleus, the cytoplasm and the plasma membrane as well as in organelles like the Golgi 
complex, the endoplasmatic reticulum and the ribosomes. CK2 activity is regulated through different 
mechanisms including recruitment into multi-molecular complexes, interaction with other proteins and 
changes in expression levels81. CK2 is a serotonin/threonine kinase that prefers phosphorylation of amino 
acids located in acidic clusters82. The general consensus is that substrates require an acidic residue in 
the position n+383,84. The minimal consensus sequence for phosphorylation by CK2 is Ser-XAA-XAA-Acidic; 
where the acidic residue can be Glu, pSer, Asp or pTyr. For this reason, CK2 has less specificity than 
other kinases, such as MEK, and phosohorylates more than 365 substrates in vitro 85 constituting 25% of 
the phosphoproteome86. However, the number of real bona fide in vivo substrates is predicted to be much 
lower87  
CK2α and CK2α’ share 90% identity despite being products of different genes88,89. Due to its enzymatic 
similarities it has been challenging to differentiate which subunit is responsible for its phosphorylation 






Image 4.1. Ribbon diagram of the crystal structure of human tetrameric CK2. PDB entry number 
1JWH. Structure determined at 3.1 A resolution. Catalytic subunit CK2α is illustrated and in  in yellow. The 
two regulatory subunits CK2β are illustrated in blue.  
 
2.2.2. Regulatory mechanisms of CK2 
 
2.2.2.1 Assembly/Disassembly of CK2 
There are different hypotheses surrounding the regulative mechanisms of CK2. One of the main hypotheses 
is that CK2 activity can be modified by regulated assembly and disassembly of the heterotetramer and even 
tetramers of higher order. There is evidence from dynamic localization studies that, in the cell, CK2α and 
CK2β can exist independently and that CK2α and CK2α´are able to phosphorylate specific substrates such 






CK2 is constitutively active and does not require phosphorylation to be activated; nevertheless, 
phosphorylation can partially contribute to its regulation. Mammalian cells have a number of 
phosphorylation sites both in CK2α and CK2β92-94. CK2β undergo autophosphorylation at Ser2 and Ser3 
close to the N-terminus 95 and can be phosphorylated in a cell cycle dependent manner at Ser20996. Instead, 
CK2α is phosphorylated in a cell cycle-dependent manner at four different amino acidic residues in their C-
terminal region and can engage in autophosphorylation at Tyr182, a site located in the activation loop in 
absence of the β subunit97.  
2.2.2.3 Small molecules 
CK2 is permanently in an active conformation and does not depend on second messengers to get activated. 
However, some small molecules like heparin can deactivate CK2 in vitro while polyamines, essential 
molecules for cell growth and differentiation, can activate the kinase in vitro and in vivo to some extent.98,99 
2.2.2.4 Protein-protein interactions 
Proteins can interact with CK2 in different modes. For example, proteins can bind to CK2 and form a 
molecular complex to increase their specificity of substrate- phosphorylation in vitro. Two examples of this 
interaction are nucleolar proteins namely, Nopp140, that associates to CK2β, or nucleolin, that binds to 
CK2α or CK2α’100,101. Fibroblast growth factors 1 and 2 (FGF-1 and FGF-2) are able to modulate 
autophosphorylation of CK2. In vitro, increasing concentrations of FGF-1 and FGF-2 bind to CK2β and 
reduce its autophosphorylation102. Reduced autophosphorylation of CK2β is correlated with a slightly 
decrease in activity103,102 . 
 CK2 interacts and phosphorylates Hsp90, a major molecular chaperone and phosphorylates Cdc37, a co-
chaperone, in vitro and in vivo104.  Hsp20-Cdc37 complex is required for the correct folding and function of 
proteins and CK2 phosphorylation of Cdc37 is essential for the function of the Hsp90-Cdc37 complex105 . 
Finally, other proteins might mediate translocation of CK2 thus, altering the ability of CK2 to phosphorylate 






2.2.3. Functions of CK2 
CK2 plays a critical role in cell proliferation, differentiation and apoptosis and it is overexpressed in many 
cancers107. Interestingly, CK2 phosphorylates several components of the PI3 kinase-Akt pathway. Akt is an 
important pro-survival kinase dysregulated in many cancers. For example, phosphorylation of Ser129 on 
Akt activates the kinase108 while phosphorylation of Ser380/Thr382/Thr383 on PTEN inactivates the 
phosphatase109. Thus, the net result of CK2 action is to positively regulate the PI3K-Akt survival pathway, 
a finding which is underlined by the fact that incubating cells with CK2 pharmacological inhibitors lead to 
apoptosis110  
Given CK2’s abnormal expression/activity in cancer, both Akt and CK2 have received special attention as 
possible targets in its treatment. Interestingly, the inhibitor CX4945 is under clinical trials (phase 2) 
(ClinicalTrials.gov Identifier: NCT02128282). Recently, the non-competitive NMDA antagonist ketamine 
has proven a fast and durable antidepressant effect possibly due to a rapid increase in synaptogenesis and 
spine formation in the PFC via the PI3K-Akt-mTOR pathway as well as reversing dendrite atrophy caused 
by stress111. Inhibition of CK2 causes inactivation of mTOR through the PI3K-Akt-mTOR pathway112.   
2.2.4.  Role of CK2 in the central nervous system 
CK2 expression is higher in the brain compared to other organs113 but its function in neurons is poorly 
understood. Some brain substrates have been identified such as the glutamate receptor, NMDAR114,115, 
alpha-synuclein or synphilin-1116 and it has also been shown to phosphorylate certain brain-specific 
transcriptional regulators, namely, the AUTS2-Polycomb complex that is often disrupted in neurological 
disorders such as intellectual disability, developmental delay and autism spectrum disorders117,118. Previous 
studies show the implication of CK2 in neurological disease such as Glioblastoma multiforme (GBM), one 
of the most aggressive human glial tumors comprising 15% of all brain tumors119. In GBM, CK2α levels are 
quadruplicated compared to a healthy brain120. Inhibition of CK2 activity through small molecule inhibitors 
or siRNA, induced apoptosis reducing growth in GBM cells in mouse xenograft models of human as well 




Parkinson´s disease (PD) is the second most prevalent neurodegenerative disorder122. CK2 is able to 
phosphorylate α-synuclein at Ser129123 (a hallmark in PD) as well as synphilin, a binding partner of α-
synuclein, altering their interaction116. In addition, previous work from our lab found evidence that CK2 
modulates the brain’s response to dopamine depletion as well as to anti-parkinsonian treatment. We 
showed that the activity of two major dopamine responsive neuronal cell types in the striatum, namely the 
direct and indirect pathway spiny projection neurons, are modulated by lack of CK2, possibly via changes 
in expression and plasma membrane availability of the dopamine D1 and the adenosine A2a 
receptors124,125. Both receptors are key players in the behavioral responses to dopamine and L-DOPA. Our 
lab found that ablation of CK2 in D1-receptor cells in a mouse model of PD alleviate L-DOPA induced 
dyskinesia (LID). Instead, depleting CK2 from D2- receptor cells aggravate the formation of LIDs. These 
findings suggest a major role of CK2 in the signaling involved in LID in the two main striatal populations of 
neurons.126 
Other neurodegenerative diseases where CK2 is a major player are: Huntington´s disease, amyotrophic 
lateral sclerosis and Alzheimer´s disease. There are several CK2 substrates that have been studied in vivo 
that play a role in neurodegenerative diseases and modification of CK2 might prove a novel target in the 
treatment of neurological and neuropsychiatric disorders127. 
Kinases are a relatively unexplored protein family in depression research, yet they have the advantage of 
being readily targeted with high specificity with small molecules. GSK3, for example, is a ubiquitously 
expressed kinase and a pharmacological target in treating affective disorders since it mediates the action 
of lithium in the treatment of bipolar disorder128. Pharmacological inhibition of GSK3 produced an 
antidepressant response in rodents129 and enhanced the antidepressant effect of sub-threshold doses of 
ketamine130,131. 
So far, the only information about expression of CK2 in the brain is derived from mRNA studies (Allen Brain 
Atlas) and western blot quantifications across some brain regions132. 
In Chapter 3 we present a small project where we mapped the expression of the three different CK2 




molecular detail about the expression of each subunit and their specific localization and allow the 






CK2 expression in the mouse brain 
Adapted from 2017 publication: Julia Castello, Andre Ragnauth, Eitan Friedman and Heike Rebholz. 
“CK2- an emerging target for Neurological and Psychiatric Disorders” Pharmaceuticals (2017) 10(1), 7 
 
3.1. Introduction 
Expression of CK2 is ubiquitous through the periphery as well as in the brain but there are interesting 
patterns, both at the transcriptional (as shown in the Allen Brain Atlas) and protein levels in the stoichiometry 
between CK2α, CK2α’ and CK2β133,134. Quantification of mRNA expression and protein level of each CK2 
subunit across different brain regions are depicted in Figure 3.1 and 3.2; from Ceglia et al (2011). At the 
mRNA level, CK2α expression is the most consistent throughout brain regions while expression of 
CK2α´and CK2β is  more heterogeneous (Figure 3.1). Overall, there seems to be an imbalance of the CK2β 
subunit when compared to CK2α and CK2α´ combined, since it resembles more closely the levels of CK2α, 
indicating that the regulatory CK2β subunit might not always be essential to the functionality of CK2α and/or 
CK2α´.  
At the protein level, CK2α predominates over CK2α´ throughout the brain. Examples are the mouse 
striatum, where the ratio CK2α: CK2α´is 8:1 and the hippocampus, where the ratio is 4:1 as indicated by 
Western Blot measurements134 (Figure 3.2).  
For this first project involving CK2, we found necessary to add information about the expression of the three 
CK2 subunits at the protein level. We performed immunohistochemical analysis of saggital brain slices to 
provide a more detailed overview of the distribution of each subunit in the mouse brain since the western 









Figure 3.1. CK2 isoform mRNA expression levels in seven major brain regions. In situ hybridizations for 
CK2α (a) CK2α´(c) and CK2β (e) on sagittal adult mouse brain. Quantification of expression levels for CK2α (b) 
CK2α´(d) and CK2β (f). CB Cerebellum, Ctx Cortex, HC hippocampus, hypo hypothalamus, Olf olfactory bulb, Str 
striatum, Tha thalamus. From Ceglia et al. Predominance of CK2α over CK2α´in the mammalian brain. Mol. 







Figure 3.2. CK2 isoform protein levels in the nine major brain regions. Western blot documenting CK2α, 
CK2α´and tubulin protein expression (a) and quantification across brain regions of CK2α (b) and CK2α’ (c). 





3.2. Materials and Methods 
Immunohistochemistry 
Animals were anesthetized with pentobarbitol and transcardially perfused with 10ml  PBS followed by 50 
ml of 4% paraformaldehyde (PFA) in PBS. PFA-perfused brains were sliced sagittally (40μm). Free-floating 
slices were washed in 3xPBS for 10min, permeabilized with PBS-T 0.05% for 10 min, blocked for 1hour 
with 10% Horse Serum and incubated in α-CK2α, α-CK2α´(Abcam), α-CK2β (gift from Dr. O. Filhol, 
Grenoble) and α-NeuN (Cell Signaling) overnight. Free-floating sections were incubated for 2 hours at RT 
with Alexa Fluor 546 or Alexa Fluor 488 (Thermo Firscher Scientific) and mounted using Prolog gold with 





Overall, mRNA levels coincided with protein levels of the different subunits across brain regions (Figure 
3.3A). However, some interesting patterns could be detected. In the hippocampus, CK2α and CK2α´ were 
present and protein expression corresponded to mRNA quantification. In the case of CK2β, mRNA 
expression was the highest in the hippocampus when compared to other brain regions, but at the protein 
level, CK2β appeared to be absent from the soma of neurons in the dentate gyrus of the hippocampal 
formation as well as from CA1, CA2 and CA3 regions (Figure 3.3A, CA2 in higher magnification in Figure 
3.3B). Nevertheless, CK2β and CK2α coexisted in most other areas and the prefrontal cortex is shown as 
representative example (Figure 3.3B´). 
The pontine grey nucleus is a region responsible for motor function regulation (Figure 3.3A) and presented 
high expression of the three CK2 subunits. Nevertheless, as indicated by NeuN staining (a marker present 
in all mature neurons except Purkinje cells, olfactory mitral cells, Cajal-Retzius cells and neurons of the 





Interestingly, CK2α was highly expressed in the olfactory bulb and the ratio CK2α: CK2α´ is 24:1. We were 
able to confirm these results by immunohistochemistry. While we clearly observed co-localization between 
CK2α and CK2β we were unable to detect any CK2α´ despite significant mRNA levels in that region (Figure 
3.3C). We identified the cells expressing CK2β as olfactory mitral cells since NeuN was not detected 
(olfactory mitral cells are one of the few cell types that are not stained with NeuN). (Figure 3.3C). 
In the cerebellum, CK2α and CK2β are homogeneously present in large GABAergic Purkinje cells, while 
CK2α´ expression was scattered. All isoforms were sporadically present in the molecular and granular 









Figure 3.3. Immunohistochemical analysis of sagittal brain slices of adult C5BL/6 mice. Slices were 




and CK2β (B). Olfactory bulb was stained for CK2β and NeuN and for CK2α’ (C). Cerebellum was stained 
for CK2α, CK2α’ and CK2β and NeuN (D) PG = Pontine grey nucleus; white bars=100µm  
 
3.2. Discussion 
Our observations at the molecular level of the expression of the three different CK2 subunits confirmed a 
ubiquitous expression mostly in all the cells with few exceptions like the hippocampus, olfactory bulb and 
cerebellum.  
In agreement with previous literature, we did not find a brain region where CK2α’ expression dominates 
over CK2α. This observation does not imply that CK2α´does not have a specialized vital function in the 
brain such as substrate-specific binding or localization to specific microdomains or subcellular structures. 
In fact, the clustered pattern seen in the Purkinje cells of the cerebellum may be of physiological relevance. 
It will be interesting to take a closer look at the expression profile on a cellular level, including the use of 
glial markers and assess the differences in subunit expression in different cell types across brain regions.  
Interestingly, we were not able to detect CK2β in the hippocampus where CK2α is homogeneously 
distributed. It is known that the catalytic subunit CK2α can be active independently from the regulatory 
subunit CK2β with a modified enzymatic activity135-137 but the study of the hippocampus could hold an 









Behavioral phenotype of the CK2 KO mice 
Adapted from 2018 publication: Julia Castello, Brice LeFrancois, Marc Flajolet, Paul Greengard, Eitan 
Friedman and Heike Rebholz. “CK2 regulates 5-HT4 receptor signaling and modulates depressive-like 
behavior” Molecular Psychiatry (2018)   23, 872-882 
 
4.1 Introduction 
The role of CK2 in neurodegenerative disorders has been barely studied. Previous work established  CK2 
as a regulator of dopaminergic signaling and its possible implication in the formation of LID in Parkinson’s 
disease. In vitro,  inhibition of CK2 increased dopamine 1 receptor (D1R) levels at the plasma membrane 
as well as adenosine 2 receptors (A2a) establishing CK2 as regulator of Gαs signaling125,138. 
Pharmacological studies of CK2 in vivo are challenging because available CK2 inhibitors like DMAT or TBB 
do not cross the blood-brain barrier (BBB)127. A promising candidate, CX4945 permeates the BBB and has 
been proven to be safe when administered orally in glioblastoma-bearing mice121. CX4945  is currently 
undergoing clinical phase II in humans as a potential treatment for cancer (ClinicalTrials.gov Identifier: 
NCT02128282). However, given the ubiquitous expression of CK2, intraperitonial administration at doses 
required for behavioral assessment in mice leads to peripheral and central side effects such as rigidity that 
need to be further characterized. To study the effects of inhibiting CK2 in the brain, KO mice can be of great 
use. Full CK2α KO mice are embryonically lethal and only survive until embryonic day E11.5 with defective 
neural tube and heart139. CK2β KO mice are reabsorbed on E7.5140. Full CK2α´mice are viable but males 
are sterile141. Therefore, we generated conditional CK2 KO mice where the α catalytic subunit was ablated 
in cells expressing the D1 receptor (Drd1a-Cre-CK2α) or in cells expressing the D2 receptor (Drd2-Cre-
CK2α) for behavioral and molecular characterization. 
Rebholz et al. previously showed that the Drd1a-Cre-CK2α KO mice, unlike the Drd2-Cre-CK2α KO mice 




the main treatment to counteract akinetic symptoms in PD, was altered in CK2 conditional KO mice. When 
the Drd1a-Cre-CK2α KO mice were placed in an open field arena, presented a hyperlocomotive phenotype 
that was normalized to WT levels after D1R antagonist administration. Interestingly, they also spent more 
time in the center of the open field when compared to WT animals.  In the novelty suppressed feeding 
(NSF) test, animals were starved for 24 hours, then placed in an open field environment with a food pellet 
in the middle of the arena. When latency to eat was quantified, the Drd1a-Cre-CK2α KO mice presented a 
reduced latency to bite the food pellet for the first time when compared to WT littermates, while the total 
food intake was not altered124. These two behaviors were indicative that the Drd1a-Cre-CK2α KO mice 
presented an anxiolytic-like phenotype. Rebholz et al further investigated the phenotype using Porsolt tests 
of behavioral despair such as the forced swim test (FST) and the tail suspension test (TST). The Drd1a-
Cre-CK2α animals were less immobile during the 4 min task than WT animals. Nevertheless, both FST and 
TST are locomotion-dependent tasks. In order to normalize locomotion levels between groups, mice were 
administered D1R antagonist, SCH (0.03 mg/kg), 10 min before testing. Although to a lesser extent, a 
reduced time immobile in the FST and TST was still significant when comparing the Drd1a-Cre-CK2α KO 
animals to their WT littermates138. 
Driven by this intriguing phenotype, we decided to further characterize the anxiolytic/ antidepressant- like 
phenotype of the Drd1a-Cre-CK2α KO mice. 
4.2 Materials and Methods 
Reagents 
Monoclonal antibody α-CK2α was purchased from Cell Signaling Technology (Danvers, MA), α-CK2α’ and 
α-CK2β from Abcam (Cambridge, MA) AND α-tubulin from Sigma (St. Louis, MO). Fluoxetine and 
Imipramine were purchased from Sigma-Aldrich (St. Louis, MO) 
Animals 
The generation of the floxed CK2α line was decribed in138 animals were bred on a C57/BI6 background. 




Laboratories (Jackson 005628, Bar Harbor, ME, USA).  Animals (4-7 months old) were used and mice were 
maintained in a 12 h light/dark cycle, with access to food and water ad libitum. Animal procedures were in 
accordance with NIH guidelines and approved by CCNY’s IACUC. 
Elevated plus maze 
The mice were placed in the middle of the elevated plus maze (50 cm from the floor) and allowed to explore 
the maze for 6 min. Time spent in open and closed arms and in the center square were scored and time 
spent in open and closed arms was plotted. 
Light-dark test 
The mice are placed in a cage divided in two equal size sections interconnected by a door. One chamber 
is opened and illuminated while the other chamber is closed and dark. The door avoids light to enter the 
dark chamber. Mice are allowed to move freely for 10 min and time spent in each chamber is quantified. 
Sucrose preference test 
The sucrose preference test was conducted using a two-bottle choice procedure using single housed mice. 
For 24 h mice were habituated to 1% (w/v) sucrose for 24 h. On day −1, mice were denied access to fluid 
but had free access to food for 16 hours. On the test day, mice were given access to the two pre-weighed 
bottles, one containing tap water and one containing 2% (w/v) sucrose, were left undisturbed for 1 hour 
before fluid consumption was measured. The test was repeated starting with re-habituation, deprivation 
and testing, and results from both tests were combined. The position of sucrose bottles were randomly 
assigned and changed. The preference for sucrose over water (sucrose/water) was used as the measure 
of the preference for sucrose. 
Nesting behavior 
Animals were single housed overnight and a square cotton pad was added to the cage. After a 16-hr period, 
scores were attributed according to the following criteria:  0: Nestlet (square cotton pat) not noticeably 
touched (more than 90% intact). 1: Nestlet partially torn (50-90% remaining intact). 2: Nestlet mostly 




Nestlet mostly shredded and gather into one flat pat. 4: Nestlet torn, > 90%, and nest built looks like a 
crater, with wall surrounding higher than mouse body height, >50%. 
Open field 
Locomotion was measured using the open field analysis in a new environment (clear Plexiglas 40 x 40 x 
30 cm open-field arena). Mice were recorded with a digital camera for the total distance moved (cm). Data 
were collected for 10 min intervals. Recordings were analyzed with Ethovision software (Noldus). 
Tail suspension test 
Mice were individually suspended by the tail from a horizontal bar (distance from floor was 35 cm) using 
adhesive tape (distance from tip of tail was 2 cm). A 6 min test session was videotaped and time spent 
immobile during the last 4 min was scored by a blind observer.  
Forced swim test 
Briefly, mice were placed in a glass cylinder (16 cm diameter, 25 cm height) filled with water (23-25°C) to 
a height of 20 cm. Immobility, defined as the absence of all motions except those required to keep the 
mouse's head above water, was determined for the last 4 min of the 6 min test. When animals were tested 
in more than one paradigm, the experiments were spaced at least 4 days apart.  
Novelty suppressed feeding 
The mice were single caged and depleted from food 24 hours before the test. Mice were placed individually 
in the corner of an open field arena filled with bedding and containing one pellet of food on a squared 
4cmx4cm paper. Latency of each mouse to grab the food pellet and take the first bite was quantified 
Sample preparation and Western Blot analysis 
All animals were sacrificed by decapitation. Animal brains were rapidily dissected. Tissues were snap-
frozen in liquid nitrogen. Tissues were lysed in 2% SDS, sonicated for 3x10 sec, boiled and cleared by 
centrifugation for 20 min at 13000 rpm. Protein concentration was determined with a BCA kit (Pierce). 30 




with CK2α, CK2α’, CK2β or α-tubulin antibodies overnight and detected by enhanced chemiluminescence 
(FluorChemE, Protein Simple). Quantification was performed using Image J software 
Immunohistochemistry 
Animals were anesthetized with pentobarbitol and transcardially perfused with a 10 ml PBS wash followed 
by 50 ml of 4% PFA in PBS. PFA perfused brains were sliced coronally (30μm). Free-floating slices were 
washed in 3xPBS for 10min, permeabilized with PBS-T 0.05% for 10 min, blocked for 1hour with 10% Horse 
Serum and incubated in α-CK2α (Abcam) overnight. Free-floating sections were incubated for 2 hours at 
RT with Alexa Fluor 546 (Thermo Firscher Scientific) and mounted using Prolog gold with dapi antifade 
reagent (Invitrogen) Imaging was performed with a Zeiss LSM710 laser-scanning confocal microscope. 
RNA extraction and real time PCR 
Brain tissue from the PFC, hippocampus and striatum was homogenized and extracted using TRIZOL (Life 
Technologies). 5 to 10µg of total RNA was treated with TURBO DNAse (Ambion) and cDNA was 
synthesized using 1-2 µg of DNA-free RNA and the High-capacity cDNA reverse transcription kit with 
random primers (Applied Biosystems). Relative mRNA levels were quantified on a Realplex PCR machine 
(Eppendorf) using Taqman gene expression assays for HTR2C (Mm00434127_m1), HTR6 
(Mm00445320_m1), S100a10 (Mm00501457_m1), HTR4 (Mm00434129_m1), HTR1B 
(Mm00493377_s1), HTR5B (Mm00439389_m1) and HTR1A (Mm00434106_s1). Relative expression was 
determined with the ΔΔCt method (Livak 2001, PMID: 11846609) using GAPDH mRNA 






4.3.1 Mood related behaviors are affected by CK2 
Animals lacking the catalytic subunit of CK2 in D1-MSN (Drd1a-Cre-CK2α), presented reduced CK2α levels 
in the striatum and the cortex. Rebholz et al. previously showed that Drd1a-Cre-CK2α mice when compared 
to WT littermates: spent less time immobile in the FST and the TST, showed reduced latency to eat in the 
NSF test and spent more time in the center of an open field arena138. To further confirm that CK2 affects 
anxiety-like behaviors, we tested mice in the elevated plus maze (EPM) and the light-dark test (LDT).  
The EPM consist of a maze with two enclosed arms and two open arms that is 50 cm elevated from the 
floor. The open arms induce an avoidance conflict while the closed arms do not142. While WT animals 
showed an inclination for the closed arm over the open arm, Drd1a-Cre-CK2α KO animals did not show a 
preference, indicative of an anxiolytic-like behavior (Figure 4.1A). The light-dark test measures anxiety in a 
non-coditionated environment – without a particular stressor143. Mice could spend time in a bright and open 
compartment or in a covered dark compartment. The Drd1a-Cre-CK2α KO mice spent significantly less 
time in the dark compartment when compared to WT littermates (Figure 4.1B). We used the sucrose 
preference (SP) test to assess anhedonia; a common condition in depressive-like states characterized by 
the inability of experiencing pleasure. In the SP test, mice are given the choice between drinking plain water 
or a 1% sucrose solution. The Drd1a-Cre-CK2α KO mice, significantly consumed more sucrose solution to 
water than WT animals (Figure 4.1C) without differences in drinking behavior or food consumption (Figure 
4.1D and 4.1E). Finally, the Drd1a-Cre-CK2α KO animals showed a reduction in nesting behavior (Figure 
4.1F). Nesting was assessed by providing a cotton pad to single caged animals over a period of 16 hours. 
While WT animals formed a volcano-shaped nest, Drd1a-Cre-CK2α KO mice left the pad almost intact. 
Whether nesting is a measure of depression-like symptoms has been controversial, but it was shown that 










Figure 4.1. Knockout of CK2α in cortex and striatum causes anti-depressant-like phenotype in 
Drd1a-Cre-CK2α KO mice. Male Drd1a-Cre-CK2α KO spent more time in the open arms of the elevated 




WT, N=11 KO) (B) Sucrose/water consumption was elevated in the male Drd1a-Cre-CK2α KO (N=14 
WT, N=13KO) (C) without changes in liquid intake (D) or food consumption (E). Nesting behavior was 
decreased in Drd1a-Cre-CK2α KO mice (N=8 WT N= KO)(F).Graphs show the mean values ±S.E.M. 
Statistical analysis was performed using two-way ANOVA with Tukey’s post-test.  F(1,52) = 12.17, p=0.001 
(A) and unpaired two-tailed Student’s test (B-F), (*P<0.05,**P<0.01, ***P<0.001)      
 
The Drd1a-Cre-CK2α KO animals presented a hyperlocomotive phenotype (Figure 4.2A and 4.2B) most 
likely due to the upregulation of the D1R in the striatum caused by the absence of CK2α125. Unfortunately, 
the nature of many of the behavioral tests used to assess depressive- and anxious- like states are 
dependent on the locomotion of subjects. For this reason, we generated Emx1-Cre-CK2α KO mice 
(CK2αfl/fl, Emx1-Cre(+/-)) that lack expression of CK2α in the cortex and the hippocampus and were not 
hyperlocomotive compared to WT littermates (Figure 4.2) We characterized the reduced expression of 
CK2α in vivo in the Emx1-Cre-CK2α line by immunohistochemistry and western blot analysis (Figure 4.3) 





Figure 4.2. Emx1-Cre-CK2α KO mice are not hyperlocomotive. Locomotion in male Drd1a-Cre-CK2α 
(A) B) and of the Emx1-Cre-CK2α mice (C,D) and WT littermates was measured as total distance travelled 
in an open field environment for 10 minutes (N= 7-8 for Drd1a-Cre-CK2α KO cohort, N=14-15 for Emx1-
Cre-CK2α KO). Plotted are mean values (± SEM). Statistical analysis was performed using two-way 
ANOVA F(1,120) = 50.75, p<0.0001 with Bonferroni’s post-tests (*, p<0.05; **, p<0.01; ***, p<0.001) (A,C)  





Figure 4.3. CK2α expression is reduced in the Emx1-Cre-CK2α KO mice. Western blotting analysis of 
male Emx1-Cre-CK2α KO or WT littermates tissues using anti-CK2α, anti- CK2α’, anti-CK2β and tubulin 
antibodies (A). The bottom band in the panel showing CK2α’ is the band that appears upon re-probing the 




expression in PFC, hippocampus and striatum using coronal slices derived from Emx1-Cre-CK2α KO or 
WT littermates using anti-CK2α antibodies (B) 
Next, we tested Emx1-Cre-CK2α mice in paradigms of anxiety and depression:  both in the TST and the 
FST, Emx1-Cre-CK2α KO animals spent less time immobile than their WT littermates (Figure 4.4A and 
4.4B).  In the EPM, WT animals spent significantly more time in the closed arm while Emx1-Cre-CK2α KO 
did not show a preference (Figure 4.4C). Furthermore, there was a significant difference in the time spent 
in the open arm between WT and Emx1-Cre-CK2α KO, being Emx1-Cre-CK2α KO higher. In the SP, Emx1-
Cre-CK2α KO preferred intake of 1% sucrose solution over water by a factor of 1.9 over WT (Figure 4.4D). 
In the NSF, the latency to eat in the Emx1-Cre-CK2α KO mice was significantly reduced compared to WT 
littermates (Figure 4.4E) without differences in their feeding behavior (Figure 4.4F).  
All the above discussed results were derived from male cohorts but we were able to reproduce the 
phenotype in female cohorts with similar results in all tests in the Emx1-Cre-CK2α and in all tests except 






Figure 4.4. Knockout of CK2 in cortex and hippocampus causes antidepressant-like behavior in 
Emx1-Cre-CK2α mice. Male Emx1-Cre-CK2α KO mice presented reduced immobility in (A) tail 
suspension test and (B) forced swim test (N=9 WT, N=11 KO for A and B), they spent more time in the 
open arm of the (C) elevated plus maze (N=7 WT, N=9 KO), consumed more sucrose to water in sucrose 




changes in food consumption (F)  (N=8 WT, N=7 KO for D,E and F). Tests performed with a cohort of 
male Emx1-Cre-CK2α KO mice and WT littermates. Graphs show mean values ±S.E.M. Statistical 
analysis was performed using two-way ANOVA with Tukey’s post-test: F(1,28)=12.03, P=0.002 (C) and 






Figure 4.5 . Knockout of CK2 causes anti-depressant-like behavior in female mice. Female Drd1a-
Cre-CK2α KO mice compared to WT littermates did not have a preference for either arm of the elevated 
plus maze (A) showed reduced immobility times in tail suspension test (B) aswell as forced swim test (C). 
Female Emx1-Cre-CK2α KO mice compared to WT littermates showed a preference for the open arm in 




swim test (F), presented reduced latency to eat in the novelty supressed feeding test (G) and increased 
sucrose/water consumption in the sucrose preference test (H). For the Drd1a-Cre mice (N=7 WT, N=7 
KO). For the Emx1-Cre ( N=7 WT, N=5 KO). Graphs show the mean values ±S.E.M. Statistical analysis 
was performed using two-way ANOVA with Bonferroni’s post test: F(1,24)=10.64, P=0.0033 (A); 







Figure 4.6. Drd1a-Cre-CK2α KO mice are more susceptible to antidepressant treatment than WT 
littermates. Mice were given an acute injection of either imipramine (N=7 WT, N=6 KO) or fluoxetine (N=11 
WT, N=10 KO) 30 min before tail suspension test (A,B). Mice were injected once daily for 15 days with 
10mg kg-1 fluoxetine. The last injection was administered 30 min before tail suspension tests (N=10 WT, 
N=9 KO) (C). Graphs show the mean values ±S.E.M. Statistical analysis was performed using one-way 
ANOVA F(1,24)=10.64, P=0.0033 (A); F(1,20)=21.55, P=0.002 (D), and unpaired two-tailed Student’s t-test 





Once confirmed the antidepressant phenotype in both KO lines, we were intrigued to test the 
responsiveness of the Drd1a-Cre-CK2α KO mice to antidepressant drugs using a tricyclic and an SSRI, 
imipramine and fluoxetine, respectively. In the TST, Drd1a-Cre-CK2α KO mice displayed a significant 
reduction of immobility time to a 5mg/kg imipramine dose while WT did not respond (Figure 4.6A). For 
fluoxetine, a dose of 20mg/kg was required for Drd1a-Cre-CK2α KO animals to respond while at this 
same dose, WT animals did not show any effect (Figure 4.6B). When fluoxetine was chronically 
administered for 2 weeks, both groups were responsive to treatment and showed a reduction of the 
immobility time in the TST although this reduction was more dramatic for the Drd1a-Cre-CK2α KO (factor 




4.3.2. 5-HT4R expression is elevated in CK2α KO mice 
Given the antidepressant- and anxiolytic- like behavior of Drd1a-Cre-CK2α KO and in Emx1-Cre-CK2α KO 
mice when compared to their corresponding WT littermates as well as the increased susceptibility to 
antidepressant drugs of the Drd1a-Cre-CK2α KO mice, we hypothesized that there must be some alteration 
in the serotonergic system. Since we previously showed that CK2 modulates Gαs signaling125, we primarily 
evaluated Gαs-coupled serotonin receptors (5-HT4, 5-HT6) as well as those 5-HT receptors that have been 
described as key players in regulating serotonergic tone (5-HT1A and 5-HT1B autoreceptors) and that were 
most relevant due to their expression profiles: we were interested in studying receptors expressed in the 
regions where CK2α was ablated in Drd1a-Cre-CK2α (striatum, cortex) and Emx1-Cre-CK2α 
(hippocampus, cortex). The 5-HT1B receptor is highly expressed in striatum and cerebellum145-148. 5-HT4 
and 5-HT6 in cortex, striatum and hippocampus55,149. We also quantified the expression profile of p11 since 
it has been found to regulate HTR4 expression and mice lacking p11 did not respond to antidepressant 
treatment150. Since the only region of overlap of Cre expression of the two mouse lines (Drd1a-Cre-CK2α 
and Emx1-Cre-CK2α) was the cortex, we focused on the prefrontal cortex (PFC) which has been described 
as a major brain substrate involved in MDD151-153. We assessed mRNA expression levels of the serotonin 
receptors by quantitative RT-PCR. We found that in the Drd1a-Cre-CK2α KO there was a 26% upregulation 
of the HTR4 while there was not a significant change in other receptors or protein p11 (Figure 4.7A). When 
quantifying HTR4 expression in the striatum, where CK2α was also ablated, we observed no difference 
(Figure 4.7B). In the Emx1-Cre-CK2α KO we found a 30% upregulation of HTR4 without alteration in mRNA 
levels of other receptors or protein p11 (Figure 4.7C). We then analyzed the expression profile of the HTR4 
in the dorsal and ventral hippocampus (Figure 4.7D and Figure 4.7E). While the dorsal hippocampus is 
involved in cognition, the ventral hippocampus plays an important role in the modulation of emotion, affect 






Figure 4.7. HTR4 expression is altered in the absence of CK2. Quantitative RT-PCR performed on PFC 
tissue (A) or PFC and striatal tissue (B) from Drd1a-Cre-CK2α KO and WT littermates (N=13 WT, N=14 
KO) for PCF and (N=6 WT, N=8 KO) for striatum; quantitative RT-PCR performed on PFC tissue (C) or 
PFC and hippocampal tissue (D) or dorsal and ventral hippocampal tissue (N=7 WT, N=7 KO) (E)  from 
Emx1-Cre CK2α KO mice and WT (males) (N=7 WT, N=6 KO). Graphs show the mean values ±S.E.M. 
Statistical analysis was performed using unpaired two-tailed Studen’s test comparing different PCR probes 








Our experiments establish a novel link between CK2α and the 5-HT4R at the transcriptional level. The first 
line of conditional CK2α KO mice, the Drd1a-Cre-CK2α, presented a behavioral phenotype reminiscent of 
antidepressant treated animals in FST, TST, EPM, NSF, SP as well as altered nesting behavior. We 
generated a second KO line, Emx1-Cre-CK2α, and mice phenocopied the Drd1a-Cre-CK2α. This line had 
the advantage that locomotor activity was not changed in CK2α KO mice, confirming the importance of 
CK2α as a modulator of depression- and anxiety-like phenotypes in mice. Importantly, while the TST and 
the FST are sensitive to acute antidepressant treatment155,156, the NSF test also showed a significant 
difference between genotypes in both mouse lines. This is particularly relevant considering that this test is 
only sensitive to chronic antidepressant treatment157, suggesting that the molecular changes caused by 
CK2 produced an effect that was comparable to chronic administration of antidepressant drugs. 
Given the phenotype of the CK2 KO mice, we hypothesized that there might be alterations in the 
serotonergic system. Thus, we tested the responsiveness of Drd1a-Cre-CK2α to antidepressant drugs and 
found that, when administered accutely, KO animals responded to lower doses of imipramine as well as 
fluoxetine. In addition, when fluoxetine was administered for 15 days, both groups responded in the TST 
but KO mice reduced the time immobile to a larger extent. These results indicate that absence of CK2 
increases susceptibility to antidepressant drug treatment.  
   
Analyzing the mRNA expression profiles of different serotonin receptors we identified a Gαs-coupled 
receptor, the 5-HT4R but not other serotonin receptors or protein p11( a protein  necessary to mediate the 
behavioral response of 5-HT4R agonist and antidepressant treatment in mice76) to be upregulated in the 
PFC of both Drd1a-Cre-CK2α and Emx1-Cre-CK2α KO mice. This upregulation was specific to the PFC 
since other brain regions where CK2α was also ablated such as striatum in the Drd1a-Cre-CK2α and  




Taken together, we found that in two different mouse lines, the absence of CK2α alters the serotonergic 
system in a very specific manner, resulting in an antidepressant- and anxiolytic- like phenotype as well as 
in an increased susceptibility to antidepressant treatment. Molecularly, ablating CK2α upregulates HTR4 in 
the PFC. Therefore, we next aim to confirm if knockdown of CK2α in adult mice, through upregulation of 
the 5-HT4R  is responsible for the antidepressant/anxiolytic-like phenotype observed in the CK2α KO mice 








CK2 regulates 5-HT4 receptor expression/signaling in vitro and in vivo 
Adapted from 2018 publications: Julia Castello, Brice LeFrancois, Marc Flajolet, Paul Greengard, Eitan 
Friedman and Heike Rebholz. “CK2 regulates 5-HT4 receptor signaling and modulates depressive-like 
behavior” Molecular Psychiatry (2018)   23, 872-882 
 
5.1. Introduction 
GPCRs are the largest protein family in the human genome and consist of over 800 members158. GPCRs 
are responsible for mediating the biological actions of neurotransmitters, hormones, pheromones, light, and 
calcium through the activation of one or more of the four G protein families: Gα i/o, Gαq/11 Gαs and Gα12/13. 
GPCR cell surface expression and coupling to G proteins are regulated by phosphorylation of their third 
intracellular loop and/or their C-terminal region by different Ser-Thr kinases159. CK2 has been described as 
capable of phosphorylating GPCRs such as M3 muscarinic receptor160. A different involvement of CK2 in 
the regulation of GPCRs in the brain was identified by Rebholz et al. following a yeast-two-hybrid screen 
assay which yielded the G protein subunit Gαs as a CK2β interacting partner in cultured cells and in brain 
tissue. The complex also contained CK2α, indicating that the CK2 holoenzyme is bound to Gαs. Only Gαs 
and no other Gα subunit precipitated with CK2β. In addition, inhibition of CK2 or siRNA targeting CK2α 
reduced agonist-induced receptor endocytosis in cultured cells and concomitantly enhanced receptor 
signaling, suggesting a negative regulation of Gαs by CK2. This regulatory effect was also observed tor the 
Gαs –coupled adenosine A2a receptor. Activation of the Gαs subunit leads to stimulation of adenylate 
cyclase which yields to accumulation of cAMP. 
MDD is linked to dysregulation of the serotonergic system in the brain. Out of the fourteen different types 
of serotonin receptors, three are coupled to Gαs.  
In chapter 4, we described how in vivo, one of the serotonin receptor subtypes, the 5-HT4R, was 




characterize how CK2 regulates 5-HT4R. For this purpose, we performed in vitro luciferase assays to 
understand possible transcriptional modifications of the activity of the HTR4 promoter. We also aim to 
identify if there is a post-translational regulatory mechanism involved. We assessed in vitro alterations in 
the expression of 5-HT4R at the plasma membrane as well as activation of the 5-HT4R through production 
of cAMP after pharmacological inhibition or knockdown of CK2. We confirmed elevated 
expression/signaling in vivo at the protein level by assessing activation of pERK, a downstream effector in 
the non-canonical 5-HT4R signaling cascade in the mPFC of mice. Unfortunately, direct 
immunohistochemical staining of 5-HT4R was not possible due to the lack of effective antibodies.  
5.2 Materials and methods 
Reagents 
Monoclonal antibody α-pThr202/Tyr204 ERK was purchased from Cell Signaling Technology (Danvers, 
MA). CX4945 was a present from Dr. S O’Brien (Cylene Pharmaceuticals). DMAT, TBB were purchased 
from Calbiochem. Sufo-NHS-LC-Biotin and streptavidin beads were from Pierce. RS67333 and GR113808 
was from Tocris (Ellisville,MO). HA-HTR4(a) in pRK5 was a gift from Dr. S. Claeysen, CNRS Montpellier, 
France, 
Cell lines 
COS7 and HeLa cells were kept in DMEM supplemented with 10% dialyzed FBS and non-essential amino 
acids at 37ºC in 95% air/5% CO2 atmosphere. Knockdown of CKα was achieved by infecting cells with a 
lentivirus expressing a CK2α-specific shRNA (pGIPZ shCK2) or non-targeting shRNA as a control (GE 
Healthcare). Briefly, cells were infected at an MOI of 10, and 72 h post-transfection, cells stably transduced 
with CK2αsh or Ctrlsh were selected for at least 7 days in presence of 2µg /mL (HeLa) and 3µg/mL (COS7) 
puromycin (Sigma). For signaling experiments, COS-7 cells were transiently transfected with HA-HTR4(a) 






A 4139 bp gDNA fragment corresponding to the region directly upstream of the mouse HTR4 mRNA first 
exon (NM_ 008313.4), was amplified by PCR using N2A  gDNA  as template,  Accuprime Pfx DNA 
polymerase (Life Technologies) and HTR4 promoter sense (5’-GGGAAGAGAGG AGAGCCTTGC-3’) and 
antisense primers ( 5’-CCTTTAGCGCAGAACCCTGC-3’) containing XmaI and BglII restriction sites, 
respectively. The resulting PCR product was digested and cloned in the XmaI/BglII sites of the pGL3B 
reporter construct (Promega). 1x105 wild-type HeLa cells were co-transfected with 750 ng each of the 
reporter construct and pCMV β-galactosidase using Lipofectamine 2000 (Life Technologies). Treatment 
with CX4945 (or DMSO) was started after 24 hours. 48h post-transfection cells were lysed in reporter lysis 
buffer. Extracts were frozen at -20˚C, thawed and cleared by centrifugation at 15,000 rpm. Luciferase and 
β-galactosidase activities were measured using luciferase assay reagent (Promega) and chlorophenol red-
β-D-galactopyranoside (CPRG, SantaCruz Biotechnologies). Relative luciferase activity was normalized to 
β-galactosidase activity to correct for transient transfection efficiency.    
cAMP assay 
COS-7 cells were treated as indicated and lysed in HCl. The concentration of cAMP from lysates was 
determined according to the manufacturer’s instructions (Enzo). 
Surface biotinylation  
Transfected COS-7 cells were washed twice with ice-cold phosphate-buffered saline containing 1 mM 
CaCl2 and 1 mM MgCl2 and then incubated twice at 4°C with 0.5 mg/ml NHS-LC-biotin (Pierce) for 20 min 
each time to biotinylate cell surface proteins (1). Cell lysate was prepared in immunoprecipitation buffer (20 
mM Tris.HCl 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton-X100, 0.1% SDS) with protease inhibitor mixture 
(Roche). Streptavidin-agarose beads (Pierce) were used to affinity purify biotinylated proteins. Quantitative 
western blots were performed on total and biotinylated (surface) proteins using NIH Image 1.63 software. 
The surface/total ratio of overexpressed HA-HT4R was calculated for each sample.  
 




Cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 
1% Triton X-
phosphatase inhibitors, and cleared by centrifugation. Protein concentration was determined with a BCA kit 
(Pierce).  30 μg of protein per well were used for SDS-PAGE, proteins were transferred onto nitrocellulose, 
incubated with antibodies overnight and detected by enhanced chemiluminescence (FluorChemE, 
ProteinSimple). Quantification was performed using ImageJ software 
Immunohistochemistry 
Male mice were injected for 7 days with saline solution. On pefusion day, mice were administered saline 
solution or GR113808 (0.1 mg/kg, i.p.), 30 min before sacrifice. Animals were anesthetized with 
pentobarbitol and transcardially perfused with a 10 ml PBS wash followed by 50 ml of 4% PFA without PBS 
wash. Brains were incubated overnight in 30% sucrose and sliced at a thickness of 30 μM. pERK 
(T202/Y204) was visualized using indirect immunofluorescence analysis (Alexa-Fluor 546 anti-rabbit IgGs 
(H+L) dilution 1:500, Invitrogen). Sections were mounted using Prolong Gold (DAPI) antifade (Invitrogen). 
Confocal microscopy was performed using a Zeiss LMS 710 laser-scanning confocal microscope using the 
same adjustments for all the sections. Counting was performed manually in 375 x375 μm confocal images 






5.3.1. CK2α regulates 5-HT4R promoter activity in vitro 
In chapter 4 we found that 5-HT4R mRNA expression was elevated in the PFC of Drd1a-Cre-CK2α KO as 
well as Emx1-Cre-CK2α KO mice when compared to their WT littermates. To determine if changes occurred 
cell autonomously in the cells lacking CK2α, we performed luciferase assays to study the activity of the 
HTR4 promoter. We used HeLa cells, a cell line that has been previously used in 5-HT4R transcription 
studies161  and cloned a 4 kb promoter fragment that corresponds to the region directly upstream of the first 
exon of the HTR4, into a plasmid harboring the reporter gene (pGL3B). In order to modulate activity, we 
inhibited CK2 pharmacologically with CX4945 or used shRNA targeting CK2α. Proof of successful CK2 
knockdown was quantified by western blot (Figure 5.1C). Both pharmacological inhibition and knockdown 
with shRNA enhanced HTR4 promoter activity by 34% and 31%, respectively (Figure 5.1A and Figure 
5.1B). These results indicate that CK2α negatively regulates transcription of HTR4. 
5.3.2. 5-HT4R-dependent signaling is controlled by CK2 activity in vitro  
We tested if a post-transcriptional mechanism may also be at play under regulation of CK2. Like Dopamine 
1 and A2a receptors, 5-HT4R is a G protein-coupled receptor. When activated, 5-HT4R signals via Gαs 
stimulating cAMP production. We overexpressed HA-tagged 5-HT4R (HA-HTR4) in COS7 cells and 
quantied cAMP production in the presence or absence of three different CK2 inhibitors: DMAT, TBB and 
CX4945 (Figure 5.2A). Overexpression of HA-5HT4R increased cAMP concentration compared to empty 
vector.  All three inhibitors succeeded in elevating cAMP. TBB led to 1.6-fold increase, DMAT to a 1.9-fold 
increase and CX4945 to a 2.3-fold increase in cAMP levels. Next, we selected inhibitor CX4945 to perform 
a dose-response experiment. As the concentration of CX4945 was increased, cAMP levels were elevated 
accordingly (Figure 5.2B). In addition, the increase in cAMP was completely blunted when COS7 cells were 






Figure 5.1. The activity of the HTR4 promoter is increased after inhibition or knockdown of CK2 in 
vitro.  Luciferase assay using HeLa cells that were transiently transfected with either empty pGL3B vector 
or vector containing the HTR4  5’UTR, after incubation with CX4945 (10µM) for 16 hours (A). Luciferase 
assay using HeLa cells that expressed shRNA against CK2α or scrambled RNA and are transiently 
transfected with either empty pGL3B vector or vector containing the HTR4 5’UTR (B) Quantifications of 
three to four independent experiments (A,B) and western blot documenting CK2α knockdown from two 
independent experiments (C). Graphs show the mean values ± S.E.M. Statistical analysis was performed 






To determine whether receptor endocytosis was affected by CK2, we performed biotinylation assays in 
COS7 cells exogenously expressing HA-5-HT4R. When cells were treated with CK2 inhibitor CX4945, the 
amount of membrane-localized receptor was 2.6-fold elevated while total levels of 5-HT4R remained 
unchanged, indicating that CK2 promotes endocytosis/desensitization of the receptor (Figure 5.2C). Co-
transfection of COS-7 cells with CK2α targeting shRNA also enriched 5-HT4R at the plasma membrane by 
4.8-fold (Figure 5.2D). Furthermore, in response to serotonin, receptor endocytosis was prevented in the 
presence of CX4945 (Figure 5.2E). 
5.3.3. 5-HT4R-dependent signaling is controlled by CK2 activity in vivo 
To confirm elevated 5-HT4R expression and signaling in vivo, we studied p42/44 ERK1/2 activation profile 
in the mPFC of mice. P42/44 ERK1/2 is a downstream effector in the non-canonical 5-HT4R signaling 
cascade that is activated and phosrphorylated following 5-HT4R stimulation162,163. We performed 
immunohistochemical analysis of inner and outer layers of the pre- and infra-limbic regions of the mPFC 
(Figure 5.3A) and observed a significant increase in both CK2α KO mice lines (Drd1a-Cre-CK2α and Emx1-
Cre-CK2α) in pERK positive cells (Figure 5.3A-G). Interestingly, Emx1-Cre-CK2α KO mice injected with 
inverse agonist, GR113808 (0.1 mg/kg, i.p.), 30 min before perfusion, showed pERK levels that were 
comparable to WT mice (Figure 5.3B and Figure 5.3C). These results indicate that the elevated pERK 
signal is due to an increase in 5-HT4R expression and/or signaling. In the hippocampus of the Emx1-Cre-
CK2α KO mice, where CK2α is also ablated, we did not observe differences in pERK signaling (Figure 






Figure 5.2. 5-HT4R-dependent signaling and expression is altered by CK2 in vitro. cAMP quantification 
of lysates derived from COS-7 cells transiently transfected with HA-HTR4 or vector incubated with CK2 




h with the indicated doses of CX4945 (B) or CX4945 (10µM) plus GR113808 (1µM) (C) before lysis and 
cAMP determination. After CX4945 treatment, cells were biotinylated and strepatavidin-precipitated HA-
HTR4  divided by the signal form total lysate derived HA-HTR4 (D,E).COS-7 cells expressing shRNA 
against CK2α or scrambled shRNA were transfected with HA-HTR4 . After 48 h, cells were lysed and 
biotinylation experiment performed and quantified (F,G). Transiently HA-HTR4-transfected COS-7 cells 
were incubated with CX4945, then stimulated with 10µM 5-HT for the indicated times. Biotinylation 
experiments were performed and quantified (H). Graphs show the mean values ± S.E.M. Statistical analysis 
for all panels is based on three independent experiments and performed using on-was ANOVA F(5,39) 
=35.29, P<0.0001 (A); F(6,28)=113.3, P<0.0001 (B); F(4,45)=26.75, P<0.0001 (C) with Bonferroni’s post test; 











Figure 5.3. 5-HT4R-dependent signaling is altered by CK2 in vivo. Scheme indicating the prelimbic and 
infralimbic portions of the mPFC in a coronal mouse brain slice (A). Immunohistochemical analysis of mPFC 
slices derived from male Emx1-Cre CK2α KO mice after 5 days of saline injection followed by acute 
GR113808 (0.1 mg kg-1, i.p.), 30 min before perfusion. Slices were incubated with anti-pERK antibody 
(T202/Y204) (B) Quantifications of the prelimbic (C) or infralimbic (D) mPFC (N=9-11). 
Immunohistochemical analysis of mPFC slices derived from male Drd1a-Cre-CK2α KO mice after 5 days 
of saline injections. Slices were incubated with anti-pERK antibody (T202/T204) (E).Quantifications of the 
prelimbic (F) or infralimbic (G) mPFC (N=5-6). Statistical analysis was performed using one-way ANOVA 
and F(3,205)=8.33, P<0.0001 (C) F(3,151)=9.726, P<0.0001 (G), Bonferroni’s post-test or unpaired two-tailed 





5.3.4 Drd1a-Cre-CK2α KO mice are more susceptible to 5-HT4R agonist treatment 
To investigate whether elevated 5-HT4R impacts on the behavioral level, we tested mice in TST or FST 
after an acute dose of the 5-HT4R partial agonist, RS67333 (0.75mg/kg, i.p.) to Drd1a-Cre-CK2α mice 
(Figure 5.4A and 5.4B). We observed that a single dose of agonist had no antidepressant effect on WT 
mice but Drd1a-Cre-CK2α KO mice showed significantly reduced immobility in the TST (76% reduction 
compared to baseline) and a trend towards reduced immobility in the FST. Suggesting increased 
responsiveness to 5-HT4R agonist administration after CK2α ablation. 
 
 
Figure 5.4. Responsiveness to 5-HT4R agonist is altered by CK2. Mice were given acute dose of 
RS67333 (0.75 mg kg-1) 30 min before tail suspension test (A) or forced swim test (B). (N=8 WT, N=7 KO). 
Graphs show the mean values ±S.E.M. Statistical analysis was performed using unpaired two-tailed 







To date, it is not known how 5-HT4R is regulated in the brain and so far, there is only information about the 
promoter, derived from human atrial tissue56. It is also unknown which are the transcription factors involved 
in 5-HT4R expression. Our experiments indicated that CK2 negatively regulates 5-HT4R transcription in the 
PFC, being 5-HT4R the only 5-HT receptor upregulated in the PFC of the Drd1a-Cre-CK2α and Emx1-Cre-
CK2α KO lines. In addition, we confirmed in vitro that the activity of the HTR4 promoter is enhanced when 
CK2 is pharmacologically inhibited or knocked down as shown by luciferase assays. We hypothesize that 
CK2 represses the HTR4 promoter by modulating the phosphorylation of a transcription factor that has not 
been yet identified. This is not surprising, since CK2 has been previously described at partaking a role in 
phosphorylating transcription factors essential for brain function like c-Fos or CREB 164,165 as well as brain-
specific transcriptional regulators such as the AUTS2-Polycomb complex that is found disarrayed in 
neuronal disorders166 or Olig2, a transcription factor necessary in oligodendrogenesis167. Importantly, when 
we performed this experiment in HEK293 cells or COS7 cells we did not observe any significant changes 
in the activity of the HTR4 promoter, indicating tissue-specificity.  Furthermore, at the post-translational 
level, CK2 is important in the homeostasis of the receptor. Stimulation of 5-HT4R increasess cAMP levels 
through activation of adenylyl cyclase. When CK2 is pharmacologically inhibited or knocked down in cells 
exogenously expressing HA-HTR4 we observed an accumulation of cAMP. This enhanced increase in 
cAMP levels response was 5-HT4R specific since co-treating the cells with 5-HT4R inverse agonist, 
GR113808 and CK2 inhibitor prevented accumulation of cAMP. 
As measured by western blot analysis in a biotinylation assay, total receptor levels were not altered after 
inhibition or knockdown of 5-HT4R and only the amount of 5-HT4R at the plasma membrane was enhanced, 
highlighting the importance of CK2 in receptor internalization. 
In vivo, there was an enhanced activation of pERK through the non-canonical G protein-independent 
pathway in the Drd1a-Cre-CK2α KO and in the Emx1-Cre-CK2α KO mice. 5-HT4R dependent activation 
was confirmed by acute administration of 5-HT4R inverse agonist that normalized pERK levels to WT levels, 




Previous studies have proven the efficacy of RS67333 to induce an antidepressant-like response in mice 
only after 3 days of treatment (as opposed to SSRI administration that require 2-3 weeks)47. We showed 
that animals lacking CK2 were more sensitive to 5-HT4R agonist treatment and displayed an antidepressant 
response after acute injection while WT littermates were non-responsive. These results indicate the 




Chapter 6  
Defining the brain region mediating the phenotype 
Adapted from 2018 publication: Julia Castello, Brice LeFrancois, Marc Flajolet, Paul Greengard, Eitan 
Friedman and Heike Rebholz. “CK2 regulates 5-HT4 receptor signaling and modulates depressive-like 
behavior” Molecular Psychiatry (2018)   23, 872-882 
 
6.1. Introduction 
Much effort has gone into the identification of the brain region/s linked to the pathophysiology of depression 
and antidepressant action. In addition to the hippocampus, the amygdala and the basal ganglia, the PFC 
has been widely implicated168. Systemic 5-HT4R agonist administration and focal overexpression of 5-HT4R 
in the mPFC increase the firing rate of DRN neurons169 establishing a role for the 5-HT4R in the positive 
feedback PFC-DRN loop which requires activation of 5-HT4R, firing of the PFC projection neurons and 
release of 5-HT from the DRN onto target structures such as the PFC, hippocampus and others2. In 
humans, functional MRI studies have linked depressive behavior to hypometabolism of the mPFC while 
deep brain stimulation of the mPFC resulted in clinical effects in treatment-resistant cases170,171. 
Postmortem studies correlated MDD with reduced neuronal cell body size, atrophy of processes and a 
reduction of glia in PFC172.  
In rodents, exposure to chronic stress causes atrophy and neuronal glial loss in the PFC and the 
hippocampus173,174. Decreased activity of the mPFC coincides with depression- and anxiety-like behavior 
and correlates with the induction of ΔFosB, specifically in the prelimbic mPFC170. Meanwhile, 
antidepressant treatment leads to increased activity of cerebral cortex175. In addition, PFC neurons 
projecting to the DRN are essential in mediating goal-directed behavior under stressful conditions since 
optogenetic activation of these PFC neurons induced an antidepressant response by increasing mobility in 




In this chapter, we investigate whether the mPFC is the anatomical brain substrate involved in the 
antidepressant- and anxiolytic-like phenotype presented in the CK2α KO lines. So far, we accumulated 
evidence to propose the PFC as the key region mediating the phenotype. First, quantification of mRNA 
expression of different serotonin receptors in the PFC, showed that only 5-HT4R was upregulated in both 
Drd1a-Cre-CK2α KO and Emx1-Cre-CK2α KO mice. This upregulation was specific to the PFC and not 
other brain regions like the striatum or the hippocampus, where CK2α was also ablated. Second, analysis 
of the phosphorylation of p42/44 ERK1/2 in vivo, the non-canonical downstream effector of the 5-HT4R 
signaling cascade, showed that Drd1a-Cre-CK2α KO and Emx1-Cre-CK2α KO mice presented enhanced 
pERK positive cells compared to WT in the inner layers of the infra- and pre-limbic areas of the mPFC. 
Furthermore, the inverse agonist GR113808 blunted this overactivation in the Emx1-Cre-CK2α KO mice 
confirming that pERK enrichment in the mPFC is mediated through enhanced levels/activity of the 5-HT4R. 
In order to fully determine the mPFC as the mediator of the antidepressant-like phenotype and discard any 
possible developmental compensatory mechanisms of the CK2α KO lines, we targeted the mPFC of adult 
mice using AAV9-mediated knockdown of CK2α or 5-HT4R as well as AAV9-mediated overexpression and 
knockdown of 5-HT4R.  
We hypothesize that knockdown of CK2α in the mPFC of adult mice would be sufficient to phenocopy the 
behavior of the CK2α KO mice and expect to observe the same molecular changes in mPFC, namely, 
enhanced pERK levels. In previous chapters, we established a role for CK2α as a negative regulator of 5-
HT4R expression and activity. We believe that the antidepressant-like phenotype was the result of 5-HT4R 
upregulation in the absence of CK2α. Thus, we expect that overexpression of 5-HT4R in the mPFC will 
recapitulate the phenotype of the CK2α KO lines.  We also performed AAV9-mediated knockdown of HTR4 
in the Drd1a-Cre-CK2α KO adult mice in order to abolish the phenotype. In addition, we quantified mRNA 
expression of HTR4, CK2α and CK2β in a postmortem analysis of the PFC of patients that suffer from MDD 





6.2. Materials and methods 
6.2.1. Viral Cre and 5-HT4 receptor expression 
Male Mice received stereotactic injections of recombinant vector AAV9-GFP or AAV9-GFP-Cre 
(AAV9.CMV.PI.eGFP.WPRE.bGH or AAV9.CMV.HI.eGFP-Cre.WPRE.SV40) bilaterally at two sites: AP 
+1.9 ML +/-0.6, DV -2.2 and -2.7 using a Kopf mouse stereotactic frame and a micropump (WPI). The virus 
was obtained from the Vector Core at the University of Pennsylvania. Per injection site, 1 μl of a viral 
concentration of 3-4 x 1013 particles/ml was used. Three weeks post injection behavioral analysis was 
performed over the course of 3 weeks and perfusions performed for IHC analysis using α-CK2 antibodies. 
For overexpression of the 5-HT4 receptor we used AAV9 virus yielding to  expression under the human 
Synapsin  promoter linked to RFP expression via an Internal ribosomal entry site (IRES) 
(AAV9.hSyn.HTR4.IRES.TurboRFP.WPRE.rBG  and as control  virus AAV9.hSyn.TurboRFP.WPRE.rBG) 
both obtained from the Vector Core at the University of Pennsylvania. Per injection site, 1 μl of a viral 
concentration of 6-7 x 1013 particles/ml was used. Bilateral injections into the mPFC were performed as 
described for the AAV9-Cre virus above. Three weeks post injection behavioral analysis was performed 
over the course of 3 weeks and perfusions performed for IHC analysis. 
For knockdown of HTR4 we used AAV9 virus expressing shHTR4 or shScrambled and linked to the 
expression of RFP under different promoters (AAV9.U6.shR.HTR4.CB7.CI.TurboRFP.SV40.delta E and as 
control virus AAV9.HI.shRScr.CMV.TurboRFP.SV40) both obtained from the Vector Core at the University 
of Pennsylvania. Per injection site, 1 μl of a diluted 1:10 solution from a viral concentration of 4.97 x 1013 
particles/ml was used. Bilateral injections into the mPFC were performed as described for the AAV9-Cre 
virus above. Three weeks post injection behavioral analysis was performed over the course of 3 weeks and 
dissections performed for qPCR analysis. 
6.2.2.Human brain samples  
Edited from Brice le Francois et al. A novel alternative splicing mechanism that enhances human 5-HT1A 





Postmortem brain tissues from subjects of both sexes were collected at autopsy at the Cuyahoga County 
Medical Examiner's Office, Cleveland, OH. Protocol was approved for recruitment, tissue collection and 
interviews of the next-of-kin by The Institutional Review Boards of the University of Mississippi Medical 
Center and University Hospitals Case Medical Center. Written informed consent was secured from legally-
defined next-of-kin. 15 depressed subjects met criteria for MDD and 9 one subject met criteria for 
adjustment disorder with depressed mood. The Structured Clinical Interview for DSM-IV Axis I Disorders 
was administered to knowledgeable informants for all subjects and diagnoses were made according to the 
Diagnostic and Statistical Manual of Mental Disorders IV (American-Psychiatric-Association, 1994), as 
described previously by Mahajan et al., 2018. All of the depressed subjects were experiencing depressed 
mood in the last month of life, and none were diagnosed with a comorbid psychoactive substance use 
disorder. Tissues were also sampled from psychiatrically normal control subjects that were matched for age 
and post-mortem interval. Gray matter was dissected with a scalpel from frozen blocks of prefrontal cortex 
and placed in an RNAse- and DNAse-free cold centrifuge tube on dry ice and then stored at -80° C. RNA 
integrity number of 90% of the PFC samples was between 4 and 8, assessed using RNA6000 picochip on 







6.3.1. Focal knockout of CK2α in mPFC yields an anti-depressant-like phenotype 
To investigate whether lack of CK2α in the mPFC is sufficient to mediate the antidepressed-like phenotype 
we injected adeno-associated virus 9 (AAV9) leading to Cre and GFP expression in CKαfl/fl mice. We 
assessed the loss of CK2α around the injection site by immunohistochemistry where cells lacking CK2α 
co-express GFP and stainned for CK2α to confirm successful knockdown (Figure 6.1A). Mice injected with 
control virus AAV9-GFP did not present loss of CK2α (Figure 6.1A). Behavioral assessment was performed 
three weeks after injection. As hypothesized, mice injected with AAV9-Cre showed significantly reduced 
immobility times in the TST (70% reduction) and FST (60.5% reduction) compared to AAV9-GFP injected 
mice (Figure 6.1B and C). When placed in the EPM, AAV9-Cre mice spent more time (+93%) in the open 
arms when compared to control animals (Figure 6.1D) and showed a reduced anhedonic-like behavior 
when assessed their sucrose to water intake ratio in the SP test (2.8-fold) without changes in their drinking 
behavior (Figures 6.1E). In the NSF test, AAV9-Cre animals presented a reduced latency to eat after a 
period of 24 hours starvation but did not show an overall increase in food intake (Figure 6.1F and 6.1G). 
Assessment of nesting behavior showed that AAV9-Cre animals failed in building a nest from cotton nestlets 
within a period of 24 hours, as previously observed in the CK2α KO mice (Figure 6.1H). These results 
clearly identify the mPFC as the region responsible of mediating the antidepressant- and anxiolytic-like 
phenotype.  
In chapter 4, we showed increased activation of pERK in cells of the inner layers of the mPFC of Drd1a-
Cre-CK2α KO as well as Emx1-Cre-CK2α KO mice when compared to WT. We wanted to corroborate if 
AAV9-Cre injected mice would also present an increased pERK activation in the mPFC. 
Immunohistochemical analysis of brain sections revealed that compared to control injected mice there is a 
significant increase of pERK levels in the inner layers of the mPFC (Figure 6.2) suggesting the involvement 
of the same molecular mechanisms in the AAV9-Cre-mediated reduction of CK2α as in the CK2α KO mouse 








Figure 6.1. Focal KO of CK2α in mPFC leads to anti-depressant-like behavior in mice. Male CK2αfFl/fl) 
mice were injected with AAV9-GFP or AAV9-GFP-Cre into the mPFC. Immunohistrochemical analysis of 
slices derived from injected animals using anti-CK2α and anti-GFP antibodies, white bar=100 µm (A). Tail 
suspension (B), forced swim test (C), elevated plus maze (D), sucrose preference test (E), novelty-
supressed feeding test (F) food consumption after novelty supressed feeding test (G) and nesting behavior 
(H) were performed with a cohort of these mice (N=10 for GFP, N=10 for GFP-Cre). Statistical analysis was 
performed using unpaired two-tailed Student’s t-test (B,C,E,F,G) (*P<0.05) and one-way ANOVA, 







Figure 6.2. ERK phosphorylation is enhanced in virally-mediated CK2α knockdown male mice. 
Immunohistochemical analysis of PFC slices derived from mice injected with AAV9-GFP-Cre or control 
mice injected with AAV9-GFP (A) Slices were incubated with anti-pERK antibody (T202/Y204). 
Quantifications of the prelimbic mPFC are shown (B) (N=10 control, N=10 Cre). Statistical analysis was 






6.3.2. Focal overexpression of the 5-HT4 receptor in mPFC yields an antidepressant-like phenotype. 
 
If focal knockdown of CK2α in the mPFC drives the antidepressed-like phenotype due to upregulation of 
the 5-HT4R, we hypothesized that focal overexpression of the 5-HT4R will mirror this behavior. We injected 
AAV9-HTR4 bilaterally in the mPFC of WT animals leading to 5-HT4R overexpression and RFP expression 
via an internal ribosomal entry site. We assessed correct site of injection by immunohistochemistry staining 
for RFP (Figure 6.3A). Three weeks after surgery, we proceeded to behavioral assessment. We were able 
to reproduce the phenotype in nearly all paradigms. AAV9-HTR4 mice presented reduced immobility times 
both in TST and in FST (40.6% and 27% respectively) (Figure 6.3B and C). In the EPM, AAV9-HTR4 
compared to control injected mice (AAV9-RFP) spent significantly more time (2.4-fold) in the open arms of 
the maze, exhibiting a preference for this arm (Figure 6.3D). Although there is a trend towards a preference 
for the consumption of sucrose solution compared to plain water this result was not significant (Figure 6.3E). 
In the NSF test, AAV9-HTR4 presented a 3-fold reduced latency to eat when compared to control mice 
(Figure 6.3F) without differences in the amount of food consumed (Figure 6.3G). As seen in the AAV9-Cre 
animals, mice overexpressing the 5-HT4R in the mPFC, also failed to build a nest over a period of 24 hours 
while control animals built a volcano-shaped nest during the same amount of time (Figure 6.3H). Taken 
together, these data clearly show that focal overexpression of 5-HT4R in the mPFC is sufficient to 
recapitulate the phenotype of the conditional CK2α KO mice and, more importantly, in mice with a virally 
mediated focal knockdown of CK2α in the mPFC, and thus are in congruence with our hypothesis that the 







Figure 6.3. Focal overexpression of 5-HT4R in mPFC leads to antidepressant-like behavior in mice. 
Male CK2α(fl/fl) mice were injected with AAV9-RFP and AAV9-HTR4 into the mPFC. Immunoshistochemical 
analysis of slices derived from injected animals, white bar=100 µm (A). Tail suspension test (B) Forced 
swim test (C) Elevated plus maze (D) Sucrose preference test (E) and novelty supressed feeding test (F) 
food consumption (G) and nesting score (H) were performed with a cohort of these mice (N=10 Control, 
N=9 HTR4 overexpressors). Statistical analysis was performed using unpaired two-tailed Student’s t-test 
(B,C,E,F,G,H) (*P<0.05, ****P<0.0001) and one-way ANOVA: F(3,40)=13.24, P<0.0001; Bonferroni’s post-





6.3.3 Focal knockdown of 5-HT4R in the Drd1a-Cre CK2α knockout mice 
Our CK2α KO mice present an antidepressed and anxiolytic-like phenotype. When we studied their mRNA 
expression profiles using qPCR we found that, from all the 5-HT receptors tested, only the 5-HT4R was 
upregulated specifically in the PFC . We injected AAV9-mediated shRNA targeting HTR4 and receptor gene 
expressing RFP in the Drd1a-Cre-CK2α KO mice to investigate whether knockdown of HTR4 would be 
sufficient to abolish the phenotype of the Drd1a-Cre-CK2α KO mice. We assessed correct site of injection 
by immunohistochemistry staining for RFP.  We accomplished a 30% reduction in HTR4 mRNA of mPFC 
tissue as shown by quantitative RT-PCR quantification (Figure 6.4A); based on our previous qPCR results 
showing that conditional CK2α KO mice present an approximate 30% upregulation of HTR4 in the PFC, 
AAV9-mediated knockdown should be sufficient to render 5-HT4R expression to WT levels.  
Three weeks after surgery we proceeded to behavioral characterization. While in the WT group knockdown 
of HTR4 did not affect behavior in the FST, in the Drd1a-Cre-CK2α KO mice group, immobility time was 
significantly elevated after shRNA mediated knowckdown of HTR4 (Figure 6.4B). We did not observe any 





Figure 6.4. Knockdown of HTR4 in the mPFC partially rescues the antidepressant-like phenotype. 
Quantitative RT-PCR performed on PFC tissue from male WT mice injected unilaterally with AAV9-sh-
HTR4-RFP (N=5) (A) Forced swim test (N=6 AAV9-Control WT, N=6 AAV9-sh-HTR4 WT, N=5 AAV9-
Control KO, N=7 AAV9-sh-HTR4 KO) (B). Graphs show mean values ± S.E.M. Statistical analysis was 
performed using unpaired two-tailed Student’s t-test (*P<0.05, **P<0.01). 
 
6.3.4. 5-HT4R, CK2α and CK2β mRNA levels are unaltered in the human PFC of depressed patients. 
In this chapter we clearly identified that alteration of CK2α as well as 5-HT4R overexpression in the mPFC 
led to changes in mood-related behaviors. Knockdown of CK2α or overexpression of 5-HT4R in mPFC 
decreased depressive- and anxious-like behavior in mice. We investigated if unmedicated patients that 
suffered MDD, presented changes in mRNA expression profiles of HTR4, CK2α and CK2β. Our results did 
not indicate the presence of significant differences in HTR4, CK2α or CK2β levels between the MDD group 
and healthy individuals (Figure 6.5A) suggesting that downregulation of HTR4 receptor or changes in CK2α 





Figure 6.5. HTR4, CK2α and CK2β mRNA levels are unaltered in MDD patients.  Quantitative RT-
PCR performed on human PFC tissue (A,B,C) (N=12 Control, N=11 MDD). Graphs show the mean 
values± S.E.M.. Statistical analysis was performed using unpaired two-tailed Student’s t-test comparing 







AAV9-mediated focal knockdown of CK2α through Cre expression in the mPFC was sufficient to mirror the 
phenotype observed in the CK2α KO lines, the Drd1a-Cre-CK2α (ablation of CK2α in striatum and cortex) 
and the Emx1-Cre-CK2α (ablation of CK2α in hippocampus and cortex). These results highlight the mPFC 
as the major region responsible for driving the antidepressant-like phenotype. Since AAV9-mediated 
injection is performed in adult mice, we corroborated that the phenotype is caused by the absence of CK2α 
and not by developmental changes induced by the embryonic KO of the CK2α KO lines associated with 
pre- or perinatal Cre expression that occurs in our mouse lines. Based on these findings, we therefore 
propose CK2α as a novel upstream player in the PFC-DRN loop regulating 5-HT4R expression specifically 
in the mPFC. 
Previous studies indicate that subchronic administration of 5-HT4R agonist result in an antidepressant 
response51. We are the first ones to show that it is sufficient to focally overexpress 5-HT4R in the mPFC to 
generate a robust antidepressive/anxiolytic-like phenotype. The behavioral outcome to focal 
overexpression is in accordance with the fact that 5-HT4R expression in glutamatergic mPFC pyramidal 
neurons regulate 5-HT levels in the DRN through a positive mPFC-DRN feedback loop169 and provides 
further rationale that the effect of CK2 is primarily driven through altered expression/signaling of the 5-
HT4R. 
Our results show that shRNA-mediated knockdown of 5-HT4R in the mPFC of the Drd1a-Cre-CK2α KO 
partially abolished the antidepressant/anxiolytic-like phenotype in the FST, where Drd1a-Cre-CK2α KO 
animals expressing shRNA-HTR4, remained significantly more time immobile than Drd1a-Cre-CK2α KO 
animals expressing scrambledRNA vector. The limitations of this approach should not be discarded. First, 
due to the lack of effective antibodies against 5-HT4R, we could only assess 5-HT4R knockdown through 
quantitative RT-PCR.  Although we achieved a 30% transcript reduction we cannot quantify the amount of 
translated protein reduction. In addition, due to breeding problems, we could not perform these experiments 
in the Emx1-Cre-CK2α animals which did not present a hyperlocomotive phenotype. The hyperlocomotion 
of the Drd1a-Cre-CK2α KO animals stems from the upregulation of the D1R in the striatum124. Thus, we did 
not expect knockdown of HTR4 to abolish hyperlocomotion. This implies that it will be unclear to discern 




Cre and the WT groups in those tests that depend on locomotor activity.  Nevertheless, partial rescue 
indicates that part of the phenotype of the CK2α KO mice is purely mediated by the 5-HT4R in the mPFC. 
On the other hand, if our results are not limited by poor protein expression or hyperlocomotion, it is important 
to consider the possibility that even though upregulation of 5-HT4R is responsible of mediating the 
antidepressant-like phenotype, a reduction of 5-HT4R levels might not reverse this behavior due to 
compensatory mechanisms. For example, we showed that, in patients that suffered MDD, levels of HTR4, 
CK2α and CK2β are unaltered in the PFC when compared to healthy individuals. Taken all together we can 
conclude that while increased levels/signaling of 5-HT4R in the mPFC generate an antidepressant-like 










Neurogenesis, spatial learning and working memory 
 
7.1 Introduction 
7.1.1 Adult Neurogenesis  
The hippocampus (HPC) is a major structure involved in cognitive processes with the ability of generating 
newborn neurons and its functionality is divided across the dorsoventral axis154,177. In mice, the dorsal HPC 
(dHPC), posterior HPC in humans, is responsible for cognition and spatial learning as well as for encoding 
contextual memory178-182.  The ventral HPC (vHPC), anterior HPC in humans,  is responsible of regulating 
mood, sociability, stress resilience180,181 and recently it has been discussed its implication in the 
pathophysiology of anxiety-related behaviors183-187. 
The dentate gyrus (DG) of the hippocampal formation is one of the few structures capable of generating 
newborn cells in the adult brain across different species. In humans, neurogenesis is still today a topic of 
controversy and in 2018, two different studies published colliding results. In the first study, Sorrells et al., 
using immunohistochemistry analysis of post-mortem brains concluded that, after childhood, neurogenesis 
events become undetectable. In the second study, Boldnini et al., using incorporation of tracers that label 
DNA of newborn neurons, concluded that neurogenesis is present during the whole human lifespan. An 
extensive review can be found in 188 where different variables of both studies are discussed such as fixation 
method, post mortem delay and selected labeling technique, etc., concluding that adult neurogenesis is 
most likely to be relevant throughout lifespan in consistency with animal studies.  
Neurogenesis has been detected across all species except for aquatic and some flying animals189. In mice, 
neurogenesis is required to mediate the effects of antidepressants and has become a marker of 
antidepressant action since administration of SSRIs significantly increased neurogenesis in the DG of the 
HPC in 2-3 weeks, a timeframe that coincides with the onset of action of antidepressant drugs49,190-192. In 




in mice only after 3 days of administration together with molecular changes characteristic of antidepressant- 
treated animals namely, increased pCREB, desensitization of 5-HT1B autoreceptors and ultimately, 
enhanced neurogenesis46,51. There is also a distinction in the role of neurogenesis across the dorso-ventral 
axis since adult-born neurons in the DG of the dHPC are required for timely acquisition of contextual 
discrimination whereas neurogenesis in the vHPC is required to mediate the effects of fluoxetine under 
certain conditions193. 
7.1.2. 5-HT4R and CK2 in learning and memory 
Cognitive impairments have been associated with MDD194,195  such as memory and attention196,197 and 
antidepressant drugs that target the monoaminergic system have been unsuccessful in reversing such 
cognitive deficits198,199. Administration of 5-HT4R inverse agonist, RS67333, in rodents, not only has been 
a promising candidate as a fast-acting antidepressant drug but also as a new treatment for the cognitive 
deficits that accompanied MDD200.  
The PI-3K/Akt pathway has been involved in the formation of long-term memory201,202. CK2 partakes a role 
in the PI-3K/Akt signaling cascade with a high degree of cross-regulation, for example, by phosphorylating 
Akt. It has been shown that CK2 activity in the CA1 region of the hippocampus decreases spatial memory 
formation203 although surprisingly, it is also involved in the induction of LTP204. 
In this chapter, given the antidepressant-like phenotype of the AAV9-Cre animals as well as the AAV9-
HTR4 overexpressing mice, we analyzed neurogenesis across the dorso-ventral axis of the HPC. We are 
interested in understanding the role of the mPFC in exerting control over the generation of newborn 
neurons. Since there is not a direct projection mPFC-HPC, our hypothesis is that, increased neurogenesis 
would be mediated by: a) the DRN through a mPFC-DRN-HPC loop where enhanced activity of 5-HT4R in 
the mPFC increases 5-HT tonus thus controlling firing at the DRN projecting to the HPC and thus enhancing 
neurogenesis or b) Neurogenesis is increased through an unknown target controlled by CK2 and 
independent of the 5-HT4R. Given the role of the 5-HT4R in restoring memory and learning deficits in mouse 
models of anxiety and depression in rodents as well as the role of CK2 in impairing spatial memory 
formation, we aim to identify whether knockdown of CK2α as well as overexpression of 5-HT4R in the mPFC 





7.2 Materials and methods 
7.2.1 BrdU incorporation and Immunohistochemistry 
Mice were injected intraperitoneally with 5'-bromo-2'-deoxyuridine (BrdU) 50mg/kg in saline solution twice 
daily for four days before intracardial perfusion with 4% PFA. Brains were transferred to 30% sucrose 
solution until sunk and sliced coronally at 30µm thickness. One out of 6 slices were selected across the 
whole hippocampus for immunostaining. A total of 10 slices per animal were selected for the dorsal 
hippocampus and 10 slices per animal for the ventral hippocampus. Slices were washed 3x with PBS for 
10 min, Incubated 10 min with HCl 1M at 4 degrees, then incubated for 20 min with HCl 2M at 37ºC, 
permeabilized for 10 min with PBS-T 0.05%, blocked with horse serum for 2 hours at room temperature 
and incubated with Brdu anti-rat primary antibody overnight at 4 degrees. The next day, slices were washed 
3x with PBS for 10 min and incubated with secondary antibody Alexa Fluor 488 anti-rat for 2 hours at room 
temperature, washed again 3x with PBS for 10 min and mounted onto coverslides with Vectorshield 
mounting agent. Imaging was performed with a Zeiss LSM710 laser-scanning confocal microscope. 
Quantification performed using Image J software. 
7.2.2 Y-maze Spontaneous Alternation  
A Y-shaped maze with three black, opaque plastic arms at a 120° angle from each other was used. Mice 
are placed at the end of one Y-maze arm and allowed to freely explore the three arms for 8 minutes. The 
number of arm entries and the number of triads were recorded in order to calculate the percentage of 
alternation between the 3 arms. An entry occurred when all four limbs were within the arm.  
7.2.3 Y- maze Spatial recognition 
A Y-shaped maze with three black, opaque plastic arms at a 120° angle from each other was used. In 
phase 1, one arm was blocked (randomly) and mice were allowed to explore for 5 min. In phase 2, the 
blocked arm was opened and mice were allowed to explore for 3 minutes, starting one hour after termination 
of phase 1. The percentage of time spent in either novel versus habituated arms was determined and 




7.2.4 Novel object recognition  
Mice were placed in the corner of an Open field arena with two identical objects placed in opposite corners 
of the subject position for 10 minutes (familiarization phase). Mice were placed a second time in the open 
field arena. In this situation,  with one of the familiar objects is removed and a novel object is introduced. 
Mice were allowed to freely explore the arena for 10 min (test phase). The amount of time spent near both 
objects was quantified. Mice were considered to explore the object when directing the nose at a distance > 
2 cm to the object and/or touching it with the nose facing the novel object and sniffing the object. Behaviors 







7.3 Results  
7.3.1. Neurogenesis in the vHPC is enhanced in the AAV9-Cre mPFC mice but not in the AAV9-5-HT4R 
mice 
After injection of AAV9-Cre or AAV9-HTR4 as described in chapter 5, mice were injected with BrdU for 3 
days twice daily before perfusion. BrdU is an exogenous, synthetic nucleoside analog to thymidine. When 
injected intraperitoneally, BrdU is incorporated during DNA synthesis205 . As a result, newborn cells can be 
detected by screening the presence of BrdU. Quantification of BrdU positive cells in the dorsal and the 
ventral hippocampus separately indicates that AAV9-Cre animals presented enhanced amount of newborn 
neurons in the DG of the vHPC but not in the DG of the dHPC. (Figure 6.7A and B).  
Surprisingly, animals overexpressing the 5-HT4R in the mPFC did not show any significant change in the 
amound of BrdU+ cells in the DG of the  vHPC nor the dHPC when compared to control animals (Figure 






Figure 7.1. Neurogenesis is enhanced in the vHPC of AAV9-Cre mPFC animals. Immunohistochemical 
analysis of of vHPC (top) and dHPC (bottom) derived from AAV-GFP-Cre mice or control mice injected with 




the ventral DG (B) or the dorsal DG (C) (N=10 control, N=10 Cre). Graphs show mean values ± S.E.M. 
Statistical analysis was performed using unpaired two-tailed Student’s t-test (*P<0.05)  
 
Figure 7.2. Neurogenesis is not altered in the HPC of AAV9-HTR4 mPFC animals. 
Immunohistochemical analysis of of vHPC (top) and dHPC (bottom) derived from AAV9-RFP-HTR4 mice 




of BrdU+ cells are shown in the ventral DG (B) or the dorsal DG (C) (N=10 control, N=10 Cre). Graphs 
show mean values ± S.E.M. Statistical analysis was performed using unpaired two-tailed Student’s t-test. 
 
7.3.2 Focal expression of AAV9-Cre-GFP in the mPFC results in a decreased performance in memory tasks 
but not overexpression of AAV9-HTR4-RFP 
Expression of AAV9-Cre in the mPFC of WT-CK2fl/fl animals had an effect in the hippocampus by 
significantly increasing neurogenesis when compared to control animals. Next, we wanted to study the 
presence of any phenotype associated with dHPC cognitive function. For this purpose, we performed three 
different behavioral assessments of spatial learning/ working memory: Novel object recognition (NOR), 
Spatial recognition (SR) and Spontaneous alternation (SA) (the later two take place using a Y-maze). 
The Y-Maze SA paradigm is based on the intrinsic tendency of rodents to explore a novel environment. 
When placed in the Y-Maze, mice are more likely to enter the least visited arm and as consequence, to 
alternate visits between the three arms of the maze. A mouse with impaired working memory will fail to 
alternate such visits.  When we quantified the number of arm alternations, AAV9-Cre mice only showed a 
trend towards decreased number of correct alternations when compared to controls (Figure 7.3A).  
The SR task involves two phases. In phase one, one arm is blocked and the mouse is allowed to freely 
explore. After an hour interval, the mouse is placed again in the Y-maze and is able to explore the entire 
maze. AAV9-Cre mice spent less time in the novel arm than control animals (Figure 7.3B) indicative of an 
impairment in spatial memory. In the NOR task, time spent exploring a familiar object and a novel object is 
quantified after a habituation phase to the familiar object. While control mice preferred to spend more time 






Figure 7.3. Spatial and working memory are impaired in AAV9-Cre mice. Percentage of correct 
alternations in Spontaneous alternation test (A) and total number of entries (B). In the Novel object 
recognition task, relative time spent exploring novel and familiar objects (C) relative time spent exploring 
two identical (familiar) objects in the habituation phase (D)  and percent of time spent in the novel arm of 
the Y-Maze in spatial recognition test (E). (N=10 control, N=10 Cre). Graphs show mean values ± S.E.M. 





When we used the same paradigms to assess the spatial learning and working memory of AAV9-HTR4-
RFP, we did not see any difference in the number of alternations between groups in the SA task (Figure 
7.4A) or in the time spent in the novel arm of the Y-maze in the SR test when compared to control-injected 
littermates (Figure 7.4B). In the NOR test, AAV9-HTR4 mice preferred to spend time in the vicinity of the 
novel object, the same behavior observed in the corresponding control animals (Figure 7.4C). This suggests 







Figure 7.4 Spatial and working memory are intact in AAV9-RFP-HTR4 mice. Percentage of correct 




novel and familiar objects (C) relative time spent exploring two identical (familiar) objects habituation phase 
(D) in the novelty suppressed feeding test and percent of time spent in the novel arm of the Y-Maze in 
spatial recognition test (E). (N=10 control, N=10 Cre). (N=10 control, N=10 Cre). Graphs show mean values 
± S.E.M. Statistical analysis was performed using unpaired two-tailed Student’s t-test (A-E) (*P<0.05) 
 
7.4 Discussion 
Neurogenesis has become a marker of antidepressant action since in mice, SSRIs are able to enhance 
neurogenesis in 2-3 weeks, timeframe that corresponds with the onset of antidepressant efficacy190-192. 
Given the antidepressant-like behavior of the AAV9-Cre and the AAV9-HTR4 animals, we were interested 
in determining whether there was increased neurogenesis in the DG across the dorso-ventral axis of the 
HPC mediated through the mPFC.  
Interestingly, the AAV9-Cre animals presented significantly higher newborn neurons, as analyzed by BrdU 
incorporation, than control animals in the vHPC while the increase in the dHPC was not significant. This is 
consistent with an antidepressant-like behavior since the vHPC and not the dHPC is responsible for 
regulating emotion and anxiety-like responses7,183,185-187,206-209. Next, we used three different tests that 
engaged the HPC to assess if there were any performance differences in working memory and spatial 
learning. We did not observe a significant difference in the SA test. Nevertheless, AAV9-Cre mice 
performed worse than their control littermates in the NOR and SR tests. The NOR task is widely used to 
assess memory alterations. However, it is also anxiety sensitive. The introduction of a novel object can 
cause an anxiety-like response in mice leading to an avoidant behavior. Since we are certain that AAV9-
Cre animals present a strong anxiolytic-like phenotype, we discarded the differences in behavior due to 
increased anxiety, but rather to an altered working memory.  
When we quantified neurogenesis in the AAV9-HTR4 animals, we were surprised for two main reasons. 
First, because AAV9-HTR4 animals presented a very strong anxiolytic-like phenotype when tested in the 
NSF. This particular test is neurogenesis dependent since mice irradiated using X-Ray targeting the HPC 
were unable to respond to antidepressant treatment or 5-HT4R agonist, RS6733351 indicating that 




to take into consideration such as, the use of a mouse model of depression (animals were long-term 
exposed to corticosterone) and received 5-HT4R agonist treatment or fluoxetine. Interestingly, our results 
suggest that, even though RS67333 administration enhances neurogenesis when compared to saline 
treated animals, this boost in neurogenesis might not be needed and just basal neurogenesis is sufficient 
to mediate the antidepressant response since AAV9-HTR4 animals did not present enhanced neurogenesis 
when compared to controls, yet displayed an anxiolytic-like behavior in the NSF. Second, because AAV9-
Cre animals did in fact present increased neurogenesis, we hypothesized that this enhancement was due 
to elevated 5-HT tonus in the DRN mediated through the mPFC rather than some mechanism involving a 
direct projection mPFC-HPC. Overexpressing 5-HT4R exerts ontrol of 5-HT concentration in the DRN45 but 
this did not mediate  neurogenesis in the HPC. When mice were tested in the same memory tasks as the 
AAV9-Cre animals, there were no significant differences in the performance between groups. 
From these results, we do not aim to link neurogenesis and performance in hippocampal memory tasks. 
Indeed, cognition is affected by the dHPC and not the vHPC, where we did not observe any difference in 
neurogenesis. Given these results we suggest that knockdown of CK2α in the mPFC most likely regulates 
one or more unknown targets independent of 5-HT4R that are responsible to mediate the altered spatial 
and working memory in AAV9-Cre rather than just an increase in serotonin, as first thought. The 









A lot of effort has been placed in the understanding of the pathophysiology of MDD and antidepressant 
action. The origin of MDD is unknown and the huge symptomatic heterogeneity of MDD makes its study 
exceptionally challenging. As an added difficulty, comorbidity with other diseases such as anxiety disorders 
is the norm and not the exception5. 
Currently, antidepressant drugs that target the monoaminergic system are the most common treatment for 
MDD. Unfortunately, they are only effective in 1/3 of the population and present a delayed onset of 
action23,24. Recently, agonists of the 5-HT4R have emerged as potential fast acting antidepressant 
candidates. Mice treated with 5-HT4R agonist, RS67333 present an antidepressant-like response only after 
3 days of treatment in contrast with SSRIs that require 2-3 weeks of chronic administration before the onset 
of therapeutic efficacy47. What is still not known the regulators of 5-HT4R expression and activity in the brain 
responsible of mediating the antidepressant-like response.  
This dissertation identifies CK2 as a novel regulator of 5-HT4R. In chapter 4, we presented an interesting 
phenotype in the conditional CK2α KO mice, the Drd1a-Cre-CK2α which lacks CK2α in striatum and cortex. 
When mice were tested in a battery of paradigms to assess anxiety- and depressive-like behaviors, Drd1a-
Cre-CK2α KO mice, displayed a phenotype reminiscent of antidepressant treated animals, even in a task 
that is only sensitive to chronic antidepressant treatment, the NSF51. Unfortunately, this mouse line also 
presented a hyperlocomotive phenotype and for this reason, we decided to corroborate the results found 
in the Drd1a-Cre-CK2α in a second mouse line that was not hyperlocomotive. We generated the Emx1-
Cre-CK2α and we were able to reproduce the phenotype in all tests in male cohorts as well as in females.  
Given this robust antidepressed- and anxiolytic-like phenotype, we investigated the underlying molecular 
mechanisms. Since both CK2 KO lines tested were reminiscent of antidepressant treated animals, we 




correspond to the main targets of antidepressant drugs. Drd1a-Cre-CK2α KO mice were more responsive 
to both TCA imipramine that targets the serotonergic as well as the norepinephrine system and SSRI 
fluoxetine that targets specifically the serotonergic system. This result is particularly interesting for two 
reasons. In the first place, because KO mice responded to TCA and SSRI at a lower dose when WT mice, 
and because the effect of chronic administration of fluoxetine was stronger in KO mice than in WT as 
measured by the fold reduction in the immobility time when comparing untreated animals with 15 days 
fluoxetine-injected mice. It will be interesting to test if co-administration of low dose of CK2 inhibitor and 
SSRI or TCA will render both a more dramatic antidepressant-like response than the antidepressant drug 
alone, if given low dosage of both there is an improvement in the side effects and if the onset of therapeutic 
efficiency is reduced. Our experiments suggest that this combination might work as a potential fast acting 
antidepressant. CX4945 has been proven to be well tolerated when orally administered in low doses and 
reducing the dose of SSRIs or TCA might be beneficial to avoid the unwanted side effects of this drugs. In 
our opinion, pharmacological inhibition of CK2 will boost the therapeutic response of current 
antidepressants. 
Since Drd1a-Cre mice are susceptible to SSRI in addition to TCA, the serotonergic system was our prime 
candidate of interest. To study possible alterations in the serotonergic system of the CK2 KO mice, we 
chose a panel of receptors based on their expression profiles coinciding with the regions of CK2α KO, and 
we found the 5-HT4R, and no other 5-HT receptor upregulated specifically in the PFC and not other brain 
regions where CK2 was also absent, for example, striatum in Drd1a-Cre-CK2α and hippocampus in Emx1-
Cre-CK2α, which indicates that CK2 negatively regulates 5-HT4R expression a the transcriptional level.  
Chapter 5 further investigates the molecular mechanisms by which CK2 regulates 5-HT4R. Specifically, we 
wanted to see if the transcriptional control extended to an enhancement of the HTR4 promoter activity and 
if a post-translational mechanism was involved as well. To further characterize CK2’s transcriptional 
regulation of HTR4, we assessed how CK2 modulates the activity of the HTR4 promoter and found in 
luciferase assays that when CK2 is pharmacologically inhibited or knocked down in vitro, the activity of the 
HTR4 promoter is increased. This experiment was performed in three different cell lines. We were only able 




of the 5-HT4R promoter161  while this was not the case when using COS7 or HEK293 cells, indicating that 
CK2 might increase HTR4 promoter activity tissue- and species-specifically. Very little is known about the 
HTR4 promoter across tissues and we just have rudimentary knowledge derived from human atrial tissue 
and placenta56,57. We have preliminary evidence that the CK2-dependent promoter element lies within a 
500 bp sequence upstream of the first transcribed exon and will continue to identify the minimal sequence 
necessary for regulation by CK2. We hypothesize that CK2, through phosphorylation, recruits a 
transcriptional repressor to the HTR4 promoter. It would be interesting in future studies to determine this 
factor and its binding region on the HTR4 gene. 
In addition to a tissue and brain region specific transcriptional regulation, we also found a post-translational 
regulation at play. Pharmacological inhibition or shRNA-mediated knockdown of CK2 in cultured cells 
enhanced the activity of the 5-HT4R by increasing cAMP levels in vitro in a dose dependent manner and 
also enriched the expression of the 5-HT4R at the plasma membrane. This effect was not due to enhanced 
transcription of the receptor since we used HTR4 expressed exogenously under a CMV promoter and 
controlled for expression by western blotting experiments. We hypothesized that CK2 is responsible for 
mediating endocytosis of 5-HT4R. Similarly, Rebholz et al previously found that CK2 negatively regulates 
D1R internalization as well as A2A receptor, another Gαs coupled receptor, but not other GPCRs coupled 
to Gi/o125. The main hypothesis is that there is a direct interaction between CK2 and Gαs, most likely through 
an accumulation of CK2 by the membrane and adjacent to the GPCR complex. This interaction needs the 
β subunit in agreement with previous studies suggesting a role for CK2β in the recruitment of the CK2 
holoenzyme to substrates, such as the transmembrane receptor CD5210. Nevertheless the substrate 
responsible for CK2 mediated –Gαs-coupled receptor signaling is not known.   
Unfortunately, available 5-HT4R antibodies lack specificity and we could not assess the protein expression 
of 5-HT4R in vivo in a straightforward fashion. Instead, we indirectly tested the phosphorylation status of 
ERK1/2, a downstream effector of the 5-HT4R signaling cascade163. Chapter 4 RT-PCR experiments 
indicated that, in the mouse brain of the CK2 KO lines, the upregulation of 5-HT4R was specific to the PFC. 
When analyzing the PFC of both WT animals and CK2 KO mice using immunohistochemical analysis, we 




both CK2 KO mouse lines (Drd1a-Cre-CK2α and Emx1-Cre-CK2α). Following 5-HT4R stimulation, ERK is 
phosphorylated Src- dependently211.  Interestingly, administration of 5-HT4R antagonist in the Emx1-Cre-
CK2α, GR111808, decreased pERK+ cells to WT levels indicating that overactivation of pERK is 5-HT4R-
mediated. As expected, we did not observe pERK differences in the HPC, where CK2α was also ablated. 
It is worth discussing that, after noxious stimulation and/or injury, ERK activation is induced after a minute 
and pERK quantification has been used as a marker neuronal marker of pain hypersensitivity212,213. For this 
reason, we injected all animals with saline solution for a week before perfusion to habituate them to the 
injection stress. 
Given the transcriptional and post-translational upregulation of 5-HT4R we wanted to investigate whether 
CK2 mice would respond to 5-HT4R agonist treatment. In agreement with our hypothesis, Drd1a-Cre-CK2α 
were more sensitive to inverse 5-HT4R agonist, RS67333, than their WT litermates in the TST. While WT 
mice did not respond to an acute dose of RS67333, immobility time of the Drd1a-Cre-CK2α KO was 
significantly reduced. 5-HT4R has been interesting in the context of new fast acting antidepressants since 
3 days of 5-HT4R administration is able to render an SSRI-like response bothe behaviorally and molecularly 
by: enhanced levels of pCREB, increased neurogenesis and increased firing of postsynaptic 5-HT1A in the 
hippocampus and desensitization of 5-HT1A autoreceptors 47. In the same fashion we found with 
antidepressant drug treatmnet, CK2 KO mice were also more responsive to RS67333, suggesting low dose 
co-administration of CK2 inhibitor together with 5-HT4R agonist a promising pharmacological approach to 
a rapid antidepressant response with less side effects. 
Taken all together, chapter 5 provides evidence that CK2 negatively regulates 5-HT4R signaling in vitro, by 
enhancing both 5-HT4R activity and expression at the plasma membrane, and in vivo, as seen by increased 
pERK in mPFC of CK2α KO mice, and behaviorally, due to their higher susceptibility to 5-HT4R agonist 
treatment.  
Chapter 6 confirms the mPFC as the region mediating the antidepressant/anxiolytic like phenotype. For this 
purpose, we knocked down CK2 in the mPFC of adult mice using adeno-associated virus. We were able to 
completely mirror the phenotype found in the CK2 conditional KO lines in all tests. These results established 




in the same region and we were also able to phenocopy the behavior, providing a rationale to confirm that 
CK2, through upregulation of 5-HT4R is responsible of mediating the phenotype.  
In addition, we hypothesized that knockdown of 5-HT4R in the mPFC, might be sufficient to abolish the 
antidepressed/anxiolytic-like phenotype of the Drd1a-Cre-CK2α. After adeno-associated virus injection of 
shHTR4 or shscrambled into the mPFC, we could partially rescue the depressive-like behavior in the FSTof 
the Drd1a-Cre-CK2α KO injected with AAV9-shHTR4 when compared to the Drd1a-Cre-CK2α KO injected 
with scrambledRNA while there was not an increase in the immobility time between the WT group (AAV9-
shHTR4 and AAV9-scrambledRNA).  Other tests, such as TST, EPM, SP or NSF   did not show any effect 
of HTR4 knockdown. In this approach, there are some technical issues that could be at stake. First, we 
were only able to quantify knockdown after viral injection by RT-PCR. Even though we were able to achieve 
a 30% reduction of HTR4 levels of AAV9-shHTR4 injected animals when compared to the control side, we 
had no control over how much this transcript reduction translates to protein expression. Furthermore, RFP 
signal in the mPFC was used to select the animals that will be considered for quantitative behavioral 
analysis which provided information about the injection quality, nevertheless, assessment of RPF might be 
misleading since, in the construct used, shHTR4 and RFP expression are driven under different promoters. 
Nevertheless, RFP stainning was still a good indicator of the injection site quality. Second, increasing the 
expression might be challenging. We performed several titrations of the virus and found that 1:10 dilution 
gave the best knockdown. Undiluted shRNA did not yield better expression and it can actually induce 
toxicity due to the depletion of the host miRNA processing machinery214. In addition, the Drd1a-Cre-CK2α 
KO is hyperlocomotive which does not render this mouse line an ideal candidate.  Knocking down HTR4 in 
the mPFC would not be sufficient to normalize locomotion to WT levels. The hyperlocomotive phenotype 
most probably originates from upregulation of the D1R in the striatum due to CK2 depletion since 
administration of D1R antagonist, SCH23390, normalizes locomotion to WT levels in the Drd1a-Cre-CK2α 
KO mice124. For this purpose, it would have been a better approach to inject shHTR4 in the mPFC of the 
Emx1-Cre-CK2α but this was not doable due to encountered problems in breeding. 
Another possible explanation would be that, even though overexpression of 5-HT4R or upregulation of 5-




not lead to depressive-like behavior. Supporting this hypothesis, 5-HT4R KO mice only presented 
depressive/anxiolytic-like behavior in certain behavioral paradigms such as reduced time spent in the center 
of the open field or decreased sucrose consumption in the SP but did not present any significant phenotype 
in NSF, TST and FST. Interestingly, KO mice presented a reduced nesting behavior215 which may indicate 
that HTR4  levels, altered in both directions disrupt normal nesting behavior. Furthermore, expression of 5-
HT4R in different brain regions might be responsible to modulate specific behaviors. In addition, while co-
treatment of fluoxetine with a 5-HT4R antagonist, GR125487 abolishes the beneficial behavioral effects of 
fluoxetine in mice, administration of GR125487 alone does not facilitate depressive/anxious-like 
responses51.  
As future experiments, it would be very interesting to study whether knockdown of HTR4 in different areas 
relevant for depression research such as the hippocampus, amygdala or basal ganglia would mediate a 
depressive-like response in different behavioral tests. Such experiment would provide a good picture of the 
role of 5-HT4R in different brain areas and which brain areas are responsible for mediating different mood 
related behavioral tasks. Since we were able to partially rescue the depressive-like phenotype in FST of 
the Drd1a-Cre-CK2α it would be of great interest to study the response to antidepressants of WT mice 
injected with AAV9-shHTR4. Even though knockdown of shHTR4 did not fully mediate a depressive-like 
phenotype, mPFC-5-HT4R might be needed to facilitate the therapeutic effect of SSRIS and reduction of 
expression may reduce the efficacy of antidepressants. For example, olfactory bulbectomized 5-HT4R KO 
mice were unable to respond to chronic fluoxetine treatment215 and the behavioral effects of fluoxetine in 
WT mice were removed when co-administered with 5-HT4R antagonist. 51 
Further confirmation that depression did not seem to stem from downregulation of 5-HT4R was that patients 
that suffered from MDD had unaltered levels of HTR4, CK2α and CK2β. 
After confirming that the mPFC is the region responsible of mediating the antidepressed/anxiolytic-like 
phenotype after knockdown of CK2, we wanted to study if modifications in the mPFC would impact the 
HPC. Neurogenesis in the DG of the HPC is established as a molecular marker of antidepressant action. 
Given the antidepressant-like behavior of floxed mice injected with AAV9-Cre mice or AAV9-HTR4, as well 




studied if these modifications in the mPFC alone would be sufficient to alter the number of adult newborn 
neurons in the HPC. In mice, both antidepressants and 5-HT4R partial agonist, RS67333, were able to 
increase neurogenesis in a timeframe that coincides with the onset of action of the drugs46. In addition, 
MDD is highly correlated with hippocampal-dependent deficits in cognition194,195 and so far, antidepressant 
drugs were able to reverse depressive and anxiety symptoms in mice but not cognition deficits198,199 while   
administration of 5-HT4R agonist, RS67333, was able to alleviate cognitive deficits in rodents200 
We found that floxed mice injected with AAV9-Cre mice presented increased neurogenesis in the vHPC 
and not the dHPC when compared to control animals. This is consistent with the notion that the vHPC is 
responsible for regulating emotion and modulating anxiety-like behaviors183,185,206. But interestingly, when 
tested in paradigms of spatial learning and working memory, AAV9-Cre mice performed poorer than their 
control littermates, AAV9-GFP. Our findings in the AAV9-HTR4 mice were quite different. As opposed to 
our expectations, these animals did not present any significant change in neurogenesis in dorsal nor ventral 
HPC and did not show any significant cognitive impairment. Based on these results,  we could conclude 
that HTR4 overexpression in the mPFC did not mediate neurogenesis in the DG of the HPC and most likely, 
knockdown of CK2 in the mPFC might regulate another target yet to be identified that would be responsible 
for the enhanced neurogenesis in the vHPC as well as the cognition deficits. Whether these two events are 
mediated through the same substrate or a different one is unknown. Based on the unexpected results, it 
would be very interesting to identify whether this enhanced neurogenesis in the vHPC is required to mediate 
the antidepressant-like phenotype. X-Ray ablation in the vHPC of the AAV9-Cre mice would shine some 
light to this question. Our hypothesis is that neurogenesis would not be required since we did not observe 
such event in the AAV9-HTR4 mice yet they did display a very robust antidepressant and anxiolytic-like 
phenotype. It has been shown that neurogenesis was required to mediate the antidepressant effects of 
fluoxetine and RS67333 in the NSF paradigm51. Our HTR4 overexpressing mice presented a reduced 
latency to eat in NSF but showed a comparable amount of BrdU+ cells to control mice. Suggesting 
enhanced neurogenesis is not required but just the ability to generate newborn neurons. 
The lack of fast-acting antidepressants poses a real problem for people suffering from MDD. We are the 




have already been tested in clinical trials for cancer treatment and are well tolerated (ClinicalTrials.gov 
Identifier: NCT02128282). Nevertheless, due to CK2 ubiquitous expression, it would be unlikely that high 
doses of CK2 pharmacological inhibitor will prove to be a successful novel antidepressant drug alone. On 
the other hand, our series of experiments involving Drd1a-Cre-CK2α animals treated with fluoxetine or 
imipramine showed that absence of CK2 increased responsiveness to antidepressant treatment and it 
would be of great interest to test whether co-administration of SSRIs and a low dose CK2 inhibitor  will lead 
to a faster antidepressant response and, in a similar manner, assess how CK2 inhibitors together with 5-
HT4R agonist could potentially exert a synergistic effect behavorally in the extent of the antidepressant 
response as well as in the onset of therapeutic. Overall, this dissertation provides evidence that protein 
kinase CK2 negatively regulates the 5-HT4R in the mPFC both at the transcriptional and the post-
translational level and that this upregulation of the 5-HT4R is responsible for mediating a phenotype 
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